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patients with metastatic cancers, but the efficacy of ACT may be limited by the ability of T cells to expand and
persist following transfer. T cells harvested from blood or tumor for ACT are often comprised of memory and
late effector subsets. Despite phenotypic and functional heterogeneity, all CD8+ memory T cell (TMem)
subsets express Fas, a tumor necrosis factor receptor superfamily member conventionally known as a death
receptor. Because Fas can mediate non-death signaling in other cell types, we hypothesized that a cognate FasFasL interaction within the tumor microenvironment might limit both T cell persistence and anti-tumor
efficacy. We discovered that FASLG, the gene encoding the apoptosis-inducing ligand FasL, is overexpressed
within the majority of human tumor microenvironments. We tested whether blockade of Fas-induced
memory T cell differentiation could improve therapeutic outcomes in multiple adoptive immunotherapy
models. Augmentation of Fas signaling in TMem using an oligomerized form of FasL enhanced cellular
differentiation and induced apoptosis. Conversely, antibody blockade (anti-FasL) of Fas signaling in TMem
culture in vitro retarded phenotypic and functional differentiation, resulting in fewer exhausted cells and
higher T cell expansion in vivo. Cell-extrinsic Fas blockade using anti-FasL provided superior anti-tumor
efficacy in multiple syngeneic murine tumor models but normalizing for differences in T cell differentiation
erased these improvements over IgG controls. Genetic engineering of Fas variants impaired in the ability to
bind FADD functioned as dominant negative receptors (DNRs) and allowed us to block Fas signaling in a
cell-intrinsic manner. This rescued Fas-competent mouse and human T cells from FasL-induced apoptosis.
Fas DNR-engineered T cells exhibited enhanced persistence within tumors following ACT, resulting in
superior cancer regression and overall survival. Despite enhanced longevity, Fas DNR-engineered T cells did
not undergo aberrant clonal expansion, demonstrating the safety of this approach. Thus, cell-intrinsic
‘insulation’ of T cells from the negative influence of FasL is a potentially universal strategy to enhance ACT
efficacy across a broad range of human malignancies.
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ABSTRACT
ENGINEERING CD8+ T CELLS TO OVERCOME DEATH SIGNALING WITHIN
THE TUMOR MICROENVIRONMENT
Tori N. Yamamoto
Nicholas P. Restifo
Adoptive cell transfer (ACT) using genetically-engineered or tumor infiltrating T cells
can have efficacy in patients with metastatic cancers, but the efficacy of ACT may be
limited by the ability of T cells to expand and persist following transfer. T cells harvested
from blood or tumor for ACT are often comprised of memory and late effector subsets.
Despite phenotypic and functional heterogeneity, all CD8+ memory T cell (TMem) subsets
express Fas, a tumor necrosis factor receptor superfamily member conventionally known
as a death receptor. Because Fas can mediate non-death signaling in other cell types, we
hypothesized that a cognate Fas-FasL interaction within the tumor microenvironment
might limit both T cell persistence and anti-tumor efficacy. We discovered that FASLG,
the gene encoding the apoptosis-inducing ligand FasL, is overexpressed within the
majority of human tumor microenvironments. We tested whether blockade of Fasinduced memory T cell differentiation could improve therapeutic outcomes in multiple
adoptive immunotherapy models. Augmentation of Fas signaling in TMem using an
oligomerized form of FasL enhanced cellular differentiation and induced apoptosis.
Conversely, antibody blockade (anti-FasL) of Fas signaling in TMem culture in vitro
retarded phenotypic and functional differentiation, resulting in fewer exhausted cells and
higher T cell expansion in vivo. Cell-extrinsic Fas blockade using anti-FasL provided
superior anti-tumor efficacy in multiple syngeneic murine tumor models but normalizing

v

for differences in T cell differentiation erased these improvements over IgG controls.
Genetic engineering of Fas variants impaired in the ability to bind FADD functioned as
dominant negative receptors (DNRs) and allowed us to block Fas signaling in a cellintrinsic manner. This rescued Fas-competent mouse and human T cells from FasLinduced apoptosis. Fas DNR-engineered T cells exhibited enhanced persistence within
tumors following ACT, resulting in superior cancer regression and overall survival.
Despite enhanced longevity, Fas DNR-engineered T cells did not undergo aberrant clonal
expansion, demonstrating the safety of this approach. Thus, cell-intrinsic ‘insulation’ of T
cells from the negative influence of FasL is a potentially universal strategy to enhance
ACT efficacy across a broad range of human malignancies.
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CHAPTER 1: INTRODUCTION
The current state of ACT for cancer
Adoptive cell transfer (ACT) using genetically engineered T cells has entered the
standard of care for patients with refractory B cell malignancies, including pediatric acute
lymphoblastic leukemia (ALL)1 and adult aggressive B cell lymphomas2,3. The efficacy
of ACT in hematologic lymphoid malignancies has been consistently observed across
clinical trials, regardless of institution, gene vector, or cell composition4-9. In Phase I and
II clinical trials, ACT for metastatic melanoma has reached overall response rates as high
as 56%10.
More recently, ACT has been shown to trigger complete and durable responses
for a handful of patients representing a variety of epithelial tumors, including cancers of
the breast, colon and cervix11-13. Epithelial tumors account for 80 to 90 percent of all of
the 600,000 cancer-related deaths in the US each year14, and several million globally15.
However, ACT has not been approved by the FDA for any solid tumor histology.
Responses to adoptive immunotherapy in patients with solid malignancies have been
comparatively modest16-20. New strategies which enhance the potency of transferred T
cells are therefore urgently needed if cell therapy is to serve a broader role in the
treatment of advanced solid cancers21.
Why is it the case that ACT in the treatment of hematopoietic tumors is FDA
approved but treatment of ‘solid’ tumors is not? Treatment of cancers with B cell origin
relies on targeting commonly expressed targets (such as CD19) that are shared with
normal B cells, which are important but not vital, given the capacity to intravenously
infuse patients with pooled immunoglobulins from healthy donors. By sharp contrast,
there is no consensus in the field that there are shared antigens expressed on tumor cell
1

surfaces that are also not expressed by vital tissues21. Treatment of epithelial tumors
clearly requires further research to discern exquisitely specific tumor antigens for T cells
to target, elucidate the characteristics of the tumor microenvironment (TME) that
supports T cell infiltration and cytolysis and innovate ways to protect a T cell from the
negative regulatory and suppressive elements of the TME. The stark differences in ACT
response rates between hematologic and epithelial tumors highlights the need to further
the field’s knowledge of the important factors governing the effectiveness of T cells in
ACT.

Historical perspective on ACT
The implications of harnessing the immune system to attack cancer started with
the observation that lymphocytes could mediate allograft rejection in mice. Later it was
demonstrated that large numbers of lymphocytes could cause regressions of transplanted
murine tumors22,23. The first studies in human cancer patients in generating an immune
response against cancer showed that administration of high doses of the T cell cytokine
interleukin-2 (IL-2), either alone or in combination with lymphocytes grown in IL-2,
could cause regressions in metastatic kidney cancer and melanoma24.
For those patients that obtained complete clinical regression of all tumors after the
use of ACT plus systemic administration of IL-2, responses were generally durable over
many years. Further studies concluded that IL-2 alone did not generate such potent
responses as the combination with lymphocytes25,26. Thorough investigations into which
lymphocyte type—cultured from excised tumors in the presence of IL-2—could induce
tumor regressions demonstrated that T cells specifically were capable of recognizing
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autologous tumor, but not healthy, cells27. These tumor-infiltrating lymphocytes (TIL)
triggered objective responses in patients with metastatic melanoma in a pilot study28.
Additional studies determined that non-myeloablative, lymphodepleting regimens
greatly increased tumor regression and T cell expansion in vivo29. The observation that
lymphodepleting preparative regimens enhance the efficacy of anti-tumor T cells have
been replicated many times in mouse models, although the mechanisms underlying this
observation remain incompletely understood. Lymphodepletion does have major effects
on the depletion of immune suppressing cells like myeloid and T regulatory cells30-33.
Also, the helpful homeostatic cytokine milieu provided by the regimen was instrumental
in understanding how host manipulation could improve ACT efficacy34.
Lymphodepletion also causes the release of TLR ligands from commensal microflora,
which likely activate innate immune cells via antigen presenting cells (APC)35. More
recently a trial has shown that the use of cyclophosphamide and fludarabine, the two
most commonly used drugs to achieve lymphodepletion, are as effective as the use of
those drugs used in combination with total body irradiation as a preparative regimen for
the ACT of TIL in the treatment of metastatic melanoma10. This knowledge can help
future studies avoid unnecessary toxicities while still preparing the patient to provide the
optimal environment to receive and support adoptively transferred T cells.
After observing early regressions using TIL to treat melanoma, then varieties of
metastatic cancers, research from many groups focused on the types of antigens that these
cells might target. It became clear that effective cultures were mainly lymphocytes, and
although more specific markers were not yet available in the early 1980’s when this work
was completed, the cells exerting the anti-tumor effects were αβ T cells that were
recognizing major histocompatibility complex (MHC)-restricted antigen36,37. Although
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researchers understood the concept of MHC-restriction from the work of Benaceraff and
Snell years earlier, a more precise nature of MHC-restriction became evident only with
the publication of the crystal structure of HLA-A2 by from Bjorkman, et al., which
vividly showed how MHC molecules function to present peptides for recognition by T
cells38.
Advancements in techniques and reagent manufacturing brought the capabilities
to enable the detailed study of immune cell phenotypes and studies revealed that
administration of T lymphocytes was correlated with response. This led to intensive
research to understand which antigens the T cells were recognizing39-41. Many different T
cells recognizing cancer-related antigens were discovered and are well covered in other
papers and reviews42-46. Discovery of shared cancer antigens, such as cancer-testis (CT)
antigens and tissue-differentiation antigens, enabled the isolation and cloning of high
avidity T cell receptors (TCR) that recognized these antigens. Encoding these TCRs in a
retroviral or lentiviral construct enabled researchers to genetically engineer large numbers
of a patient’s own peripheral blood-derived T cells to express a TCR known to target a
cancer antigen with high avidity.
Concurrently, studies in pre-clinical mouse models demonstrated that less
differentiated T cells—those cells capable of expressing IL-2 and proliferating upon
adoptive transfer—mediate better anti-tumor efficacy in comparison to more
differentiated or exhausted T cells47-49. Phenotypic studies elucidated that TIL were often
highly differentiated T cells expressing markers associated with senescence or
exhaustion50, suggesting that perhaps those patients whose cancer did not undergo
regression after ACT were given ineffective T cells. The implications of these data led
researchers to isolate TCRs that could be genetically overexpressed in younger, less
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differentiated T cells that might mediate a more potent anti-tumor effect (covered in more
detail in the next section). Unfortunately, early attempts at TCR gene therapy directed at
tissue-differentiation antigens revealed that antigens like MART-1, gp100 and CEA were
also expressed on normal tissues. Recognition of these antigens with high avidity TCRs
resulted in frequent “off-tumor, on-target” toxicities in the form of vitiligo, hearing loss,
visual compromise and colitis17,51-53.
Not all TCRs directed against shared cancer antigens have been abandoned,
however. Others have identified shared antigens are selectively expressed on many types
of cancers, such as NY-ESO-1, and have isolated high avidity TCRs to target this
antigen54,55. While ACT of genetically engineered T cells expressing an NY-ESO-1specific TCR has been found safe in both melanoma and synovial cell sarcoma patients,
there are very few patients that actually express high enough levels of these antigens and
are deemed eligible for treatment with these TCRs56.
Another example of a shared cancer antigen that has acceptable off-tumor
toxicities is CD19, a protein expressed by many B-cell malignancies but also expressed
on normal B cells. Current efforts target this shared antigen through the use of chimeric
antigen receptors (CARs) which connect antibody recognition domains to the
intracellular TCR signaling components of CD3z and a costimulatory domain (e.g. CD28
or 4-1BB)1,2. CAR-transduced T cells can be directed against any surface protein or
molecule on the cell surface without the need of HLA presentation, allowing any patient
with shared antigen expression to take advantage of this reagent.
A key constraint of CARs in the treatment of cancer is that CARs recognize only
peptides present in proteins expressed on the surface of the tumor cell, not peptides
presented in the context of MHC presentation. This approach negates the targeting of
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intracellular proteins. Profoundly, researchers have conclusively identified only a few
antigens that are present on tumors but not also expressed on the surfaces of vital healthy
tissues.
CAR-transduced T cells can recognize mutated antigens expressed on the surface
of tumor cells as evidenced by the identification of the epidermal growth factor receptor
variant III (EGFRvIII) expressed on the brain cancer glioblastoma multiforme (GBM).
EGFRvIII is a variant of the normal EGFR receptor that has had exons 2-7 deleted, and
because it is expressed by 30% of tumors of patients with GBM this mutated antigen has
been targeted. The usefulness of this antigen remains to be seen in the face of potentially
fluctuating levels of EGFRvIII on the surface of GBM57, and in a Phase 1 trial the early
results have been minor and difficult to attribute solely to CAR activity58. These reported
findings are in line with early results in a similar trial currently recruiting at the National
Cancer Institute (NCI). Thus, the dearth of surface targets with acceptable off-tumor
toxicities remains a major limiting factor in advancing CARs in the setting of solid
tumors, and off-the-shelf reagents might very infrequently be utilized for ACT.
Regardless of the antigen chosen, or whether TIL or T cells genetically
engineered to express a TCR or CAR are utilized, the rates of success of ACT leave
much room for improvement. Further understanding of the ways in which to improve T
cell function and capabilities could lead to an increase in the overall response rates of
cancer to ACT.

Factors influencing T cell differentiation and function
Multiple variables may influence the success or failure of transferred T cells to
mediate cancer regression59. These can include the state of T cell differentiation60 and
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local immune-suppressive factors present within the tumor-bearing host61. Despite these
complexities, one of the single most consistent correlates of response observed in both
hematologic2,4-6,8 and solid cancers16,20,62-64 has been the expansion and/or persistence of
transferred T cells following infusion.
Previous work in our lab has demonstrated that the differentiation status of CD8+
T cells is important when mediating anti-tumor effects in vivo47,49,65. Using surface
molecules CD44 and CD62L as differentiation markers, our group analyzed the in vivo
efficacy of various antigen-experienced cells: T stem cell memory (TSCM) which are
defined as CD44loCD62Lhi; T central memory (TCM), defined as CD44hiCD62Lhi; and T
effector memory (TEM), defined as CD44hiCD62Llo. Our group found that less
differentiated, or younger, T cells (e.g. the TCM and TSCM populations with high CD62L
expression, longer telomeres and the presence of TCR excision circles49) can mediate
superior tumor regression in the pmel-1 melanoma tumor model66. Furthermore, it has
been shown that CD27 expression and longer telomere length (both associated with
younger T cells) and persistence of T cells one month after transfer are correlated with
partial and complete responses in melanoma patients62. This intriguing finding indicated
to us that we should concentrate our efforts on preserving a less differentiated phenotype
of our T cells for ACT60.
However, there are many reasons why currently we are unable to make use of
younger cells in ACT. The starting population of T cells available for ACT are frequently
late effector and effector memory from tumor infiltrating lymphocytes, or peripheral
blood lymphocytes containing a dearth of naïve and younger T cell subsets due to
intensive chemotherapy treatments. Our cell expansion methods drive these cells further
down the differentiation pathway both phenotypically and functionally and could inhibit
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the in vivo long-term persistence of the adoptively transferred cells. Based on our mouse
studies we hypothesize that limiting phenotypic and functional differentiation during ex
vivo culturing of T cells for ACT will increase our chances of successful ACT for
multiple tumor treatments.

Fas signaling in T cells
Our studies aimed at understanding T cell differentiation and functionality
uncovered an unexpected phenomenon: that naïve T cells grown in the presence of
antigen-experienced T cells differentiate faster than naïve cells stimulated alone. Culture
of congenically-marked, naïve CD8+ T cells (TN) alone or in the presence of increasing
concentrations of differentially marked antigen-experienced CD8+ T cells demonstrated
that TN cells cultured with antigen-experienced cells had differentiated to CD44+CD62LTEM, whereas naïve cells grown alone had differentiated mostly into TCM67. This
differentiation was also reflected in a marked increase in the production of interferongamma (IFNg). This differentiation effect observed was cell dose-dependent, cell
contact-dependent and can only occur after TCR stimulus. Microarray analysis of the
results revealed that Fas ligand (FasL) was much more highly upregulated in the mixed
cell cultures. Upon further characterization of T cells before and after TCR stimulation,
we found that the receptor for FasL, Fas, is upregulated on both naïve and antigenexperienced cells, but FasL is expressed only on antigen-experienced cells after TCR
stimulation. Fas and FasL are members of the tumor necrosis factor (TNF) superfamily,
which is comprised of members that have co-stimulatory and/or death-promoting
properties68. Fas is canonically known to be a death receptor: signaling begins after Fas
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trimers dimerize around FasL, then aggregate in lipid rafts before binding to adaptor
molecule FADD and activating procaspase-8 and the extrinsic apoptotic cascade69.
In consequent studies, we found that stimulation of the Fas receptor through the
use of an oligomerized FasL construct (lz-FasL) can drive differentiation of CD8+ TN
cells, resulting in more TEM and more IFNg production with higher levels of lz-FasL
added to the cultures67. Additionally, we found that Fas blockade using a blocking
antibody to FasL (anti-FasL) preserves a younger phenotype even when TN are grown in
the presence of antigen-experienced T cells. The naïve cells where Fas signaling was
blocked also produced less IFNg, indicating less differentiated cells, when compared to
naïve and antigen-experienced cells mixed together. Using anti-FasL during ex vivo
cultures of CD8+ TN cells demonstrated that in vitro blockade of Fas can result in more T
cells preserving high expression of CD62L, and these less differentiated T cells can then
mediate a superior effect on tumor growth, which also correlates with improved survival
in treated mice.
These experiments demonstrating a non-death role for Fas in primary T
lymphocytes were not the first known instances of the non-apoptotic Fas signaling. Early
experiments with antibodies stimulating Fas demonstrated that not only could Fas
signaling induce apoptosis, but when Fas signaling occurred concurrently with TCR
stimulus Fas stimulation could induce proliferation and increase cytokine production in
human, peripheral blood T cells70. Subsequent work by others has linked non-apoptotic
Fas signaling in non-lymphocytes to the PI3K signaling pathway71-73. In glioblastoma
cancer cells, the Martin-Villalba lab has found that binding of FasL to Fas induced
migration by recruiting Src family kinase Yes and activating the PI3K pathway74. They
have also found that in neural stem cells, FasL treatment of Fas-expressing neural stem
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cells induced differentiation into early stage neurons through the recruitment of the Src
family kinase pp60 and activation the PI3K pathway75. Our own data in CD8+ TN
indicates that Akt is phosphorylated after oligomerized-FasL stimulation during T cell
activation at greater levels in comparison to cells stimulated in the presence of vehicle67.
These intriguing results with Fas stimulation and blockade led us to hypothesize that Fas
modulation will enable the preservation of a younger phenotype of T cells for ACT, thus
enabling us to give a cell product that could better mediate tumor regression in vivo.

Rationale
Building upon these observations and the desire to improve ACT response rates in
cancer patients, we hypothesized that disruption of factors which negatively regulate T
cell proliferation and survival might represent potentially actionable pathways to enhance
adoptive immunotherapies. Several clinical trials have tested whether cell-extrinsic
approaches, such as the co-administration of an immune-checkpoint inhibitor76,77, can
improve the persistence of adoptively transferred T cells. Early results are mixed,
however, indicating that modulation of other pathways should be explored. Previous
work in our lab demonstrated that Fas signaling blockade, through use of a blocking
antibody specific for FasL, could protect CD8+ TN from differentiation in vitro. This
could represent a simple approach to the maintenance of younger T cells during ex vivo
expansion for ACT. While it is unclear whether memory CD8+ T cells would be afforded
this same protection, we hypothesized that Fas signaling blockade could improve
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memory CD8+ T cell function during ACT (Figure 1, top).

Fas-FasL signaling during T cell activation
Fas

TCR

FasL

• Effector differentiation
• Fewer cells

Cell-extrinsic or cell-intrinsic blockade of Fas signaling
Fas DNR
overexpression

Blocking
FasL
antibody

xx
xx x x

• Less differentiation
• More survival

Figure 1. Proposed cell-extrinsic and cell-intrinsic means to block Fas-FasL signaling.
After TCR activation during in vitro T cell cultures, memory CD8+ T cells upregulate FasL, allowing for the apoptotic
signaling cascade to occur on memory CD8+ T cells that concurrently express Fas (top). This could result in further
effector differentiation of activated T cells, as well as fewer cells generated due to FasL-mediated apoptosis. We
hypothesize that blockade of Fas-FasL signaling could work to prevent excess differentiation during in vitro cell
culturing and prevent Fas-mediated apoptosis (bottom). Blockade of Fas-FasL interactions during cell culture could be
accomplished using a blocking FasL antibody that prevents FasL binding to Fas. Alternatively, overexpression of a Fas
dominant negative receptor (DNR), mutated to prevent Fas apoptotic signaling, could also prevent Fas-mediated
death and differentiation.

However, it is possible that cell-extrinsic agents such as anti-FasL may not
improve T cell function in vivo. We therefore also pursued a cell-intrinsic strategy to
enhance function exclusively within tumor-specific T cells, thereby containing the risk of
systemic toxicities and taking full advantage of the ability to reliably genetically engineer
human T cells for clinical applications. Overexpression of a mutated Fas molecule,
disabled in its ability to bind FADD and activate the extrinsic apoptotic signaling
cascade, could provide a means to protect CD8+ T cells from both death and
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differentiation mediated by Fas-FasL signaling (Figure 1, bottom). This cell-intrinsic
means of disrupting Fas signaling would be carried with the T cell during adoptive
transfer, allowing us to interrogate if protection from Fas-mediated programmed cell
death is an important factor during ACT.
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CHAPTER 2: FAS AND FASL EXPRESSION IN THE CANCER PATIENT
Abstract
One of the few consistent correlates of response for adoptive T cell therapy in the
treatment of cancer is T cell persistence. While the Fas receptor is known to cause death
and differentiation in many cell types, it is not clear if Fas and its ligand, FasL, are
present on cancer patient T cells or in the tumor microenvironment. Based on our results
with naïve CD8+ T cells, we hypothesized that FasL would be present in the tumor
microenvironment during ACT. Using a pan-cancer analysis to identify candidate ligands
which might limit the ability of T cells to expand and persist within the tumor-bearing
host, we discovered that the canonical apoptosis-inducing ligand FASLG is preferentially
expressed in the majority of human tumor microenvironments. Further, we found that
most therapeutic T cells used for adoptive immunotherapy constitutively express Fas, the
cognate receptor for FasL. These results indicate that Fas signaling could play an
important role during adoptive T cell therapy for cancer.

Human tumor microenvironments overexpress the death-inducing ligand FASLG
Across human ACT clinical trials for both hematologic and solid cancers, in vivo
T cell expansion and persistence have positively correlated with clinical responses4-6,16,63.
These observations led us to hypothesize that disruption of pathways that impair T cell
proliferation and survival might represent exploitable targets for improving outcomes
following adoptive transfer. To determine whether ligands that negatively modulate T
cell proliferation and survival are enriched within human TMEs, we compared RNAsequencing data using tumor-containing samples from the TCGA database
(https://cancergenome.nih.gov/) relative to matched normal tissues of origin. Given
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recent evidence that tissues adjacent to resected tumors possess an inflamed
transcriptomic profile reflective of an intermediate state between transformed and nontransformed tissues78, we used expression data from the Genotype-Tissue Expression
(GTEx) database79 as a normal control. In total, we analyzed 9,330 samples obtained
from 26 different cancer types for which an appropriate matched tissue of origin was
available (Appendix, Supplemental Table 1). Raw data from each dataset was extracted
and normalized in an identical fashion using the RNA-Seq by Expectation Maximization
(RSEM) method80.
We discovered that expression of FASLG, the gene encoding the canonical
inducer of cellular apoptosis FasL (CD178), was overexpressed in the majority of
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evaluated cancer types relative to normal tissues (Figure 2A).

Figure 2: Human tumor microenvironments overexpress the death-inducing ligand FASLG.
(A) A pan-cancer analysis of FASLG expression within the microenvironments of 26 different tumor types relative to
matched normal tissues of origin. RNA-sequencing (RNA-seq) data from 9,330 human cancers and matched normal
tissues was extracted from the Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression datasets, analyzed using
UCSC Xena, and displayed as normalized RNA-Seq by Expectation Maximization (RSEM) values. Statistical comparisons
of expression between tumors and normal tissues were made using a Mann-Whitney t test with Bonferroni
correction; ***P<0.001, **P<0.01, *P<0.05. (B) Selected, pre-ranked gene set enrichment analyses (GSEAs) against all
KEGG pathways of genes positively correlated to FASLG expression averaged across 26 TCGA histologies. Circle
diameters reflect the number of genes identified within the GSEA signature sets. The nominal P-value and FDR q value
for all displayed GSEAs were <0.001. (C) Pearson’s correlation of the top 200 correlated genes to FASLG gene
expression across 26 human cancer types in the TCGA database. Selected immune-related genes associated with the
GSEA signature sets listed in panel (B) are identified.
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This included both immunotherapy responsive cancers, such as cutaneous melanoma
(SKCM), renal clear cell carcinoma (KIRC), lung adenocarcinoma (LUAD), and gastroesophageal carcinomas (STAD/ESCA), as well as cancers relatively recalcitrant to
current immunotherapies, such as breast carcinoma (BRCA), colorectal adenocarcinoma
(READ/COAD), glioblastoma multiforme (GBM), ovarian cancer (OV), pancreatic
adenocarcinoma (PAAD), and prostate adenocarcinoma (PRAD). In total, we discovered
that 73% (19/26) of the human tumor types evaluated exhibited significantly higher
expression of FASLG within the tumor mass relative to normal tissue controls (P < 0.05
to P < 0.001; Mann-Whitney t test, Bonferroni-corrected). By contrast, only 19% (5/26)
of cancer types did not exhibit significant differential expression and only a minority
(8%; 2/26) showed evidence of reduced FASLG expression in tumor samples versus
normal tissue.
To gain greater insight into the nature of FASLG expression within human TMEs,
we performed gene-set enrichment analysis (GSEA)81 using genes positively correlated
with FASLG across all 26 evaluated cancer types (Figure 2B). We found that expression
profiles for many immune-related pathways, including NK cell cytotoxicity, antigen
processing and presentation, TCR signaling, primary immune deficiency, and apoptosis,
were each significantly enriched (nominal P-value <0.001, FDR q value < 0.001).
Consistent with these findings, examination of the top 200 genes positively correlated
with FASLG revealed a predominance of markers associated both with lymphocyte
activation, such as IFNG, PRF1, 41BB, and ICOS, and immune counter-regulation,
including PDCD1, LAG3, and IL10RA (Figure 2C and Appendix, Supplemental Table 2).
The finding that FASLG expression was positively associated with immunerelated pathways led us to interrogate how FASLG expression might correlate with
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patient survival. To answer this question, we again examined the primary tumor samples
available in the TCGA dataset and correlated high versus low FASLG expression with
patient survival. In the majority of untreated primary tumor histologies (27 of 34; 79%)
for which tumor sample data was available, there was no significant correlation between
high or low FASLG expression and clinical outcome (data not shown). For four
histologies—specifically BRCA, head and neck squamous cell carcinoma (HNSC),
chromophobe renal cell carcinoma (KICH) and metastatic SKCM—higher FASLG
expression correlated with improved overall survival (Figure 3A).
High FASLG expression correlates with better survival: 4/34 (11.8%)

Proportion of patients surviving

A

Time (days)

Low FASLG expression correlates with better survival: 3/34 (8.8%)

Proportion of patients surviving

B

Time (days)

No correlation of FASLG expression with better survival: 27/34 (79.4%)

Figure 3. Correlation of FASLG expression in patient tumors and patient survival.
A) Kaplan-Meier survival plots for tumor samples where high FASLG gene expression correlates with better survival.
BRCA is breast carcinoma, HNSC is head and neck squamous cell carcinoma, KICH is chromophobe renal cell
carcinoma, metastatic SKCM is metastatic skin cutaneous melanoma. B) Kaplan-Meier survival plots for tumor
samples where low FASLG gene expression correlates with better survival. LGG is lower grade glioma, THYM is
thymoma, UVM is uveal melanoma. For 27/34 histologies no correlation was observed between FASLG expression
and patient survival, data not shown. Survival curves compared using log-rank test.

Conversely, positive correlation of patient survival with low expression of FASLG
was demonstrated in the patient tumor samples from lower grade glioma (LGG),
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thymoma (THYM) and uveal melanoma (UVM) (Figure 3B). An analysis by Zhu et al.
also found similar results in their analysis of the samples in the TCGA dataset61. These
data imply that FASLG gene expression does not consistently correlate positively or
negatively with patient outcome, which seems reasonable given these patients would
have been treated with a variety of anti-cancer agents, including immune-modulating
agents.
Taken together, these data indicated that a death-inducing ligand which might
compromise T cell survival is significantly overexpressed in the majority of human
cancer microenvironments and is highly correlated to expression signatures of immune
activation and regulation.

Human patient T cells express high levels of Fas
We next sought to determine whether Fas (CD95), the cognate receptor for FasL,
is expressed on the surface of T cells used for clinical adoptive immunotherapy.
Previously, we and others found that Fas is expressed on all non-naïve human T cell
subsets from healthy donors (HD), including TCM, TEM, and effector memory T cells coexpressing CD45RA (TEMRA)49,82. Using apheresis products used to generate therapeutic
T cells for ACT from patients with melanoma (MEL) or aggressive B cell lymphomas
(DLBCL), we analyzed both the distribution of CD8a+ T cell subsets and the frequency
of Fas expression on these subsets. Comparison was made to circulating T cells obtained
from a group of age-matched HDs. Consistent with previous reports, we found high
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expression of Fas on the TCM, TEM, and TEMRA subsets (Figure 4, A and B).
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Figure 4. Fas expression is higher in patient PBMC.
(A, B) Representative histogram (A) and summary plot of Fas MFI (B) on phenotypically defined CD8a+ T cell subsets.
Data shown are from peripheral blood T cells from 47 patients and HDs. CD8a+ T cell subsets in panels (A) and (B)
were defined as follows: TN cells, CD8a+CD45RA+CD45RO-CCR7+CD62L+CD27+CD28+Fas-; TCM,
CD8a+CD45RO+CD45RA−CCR7+CD62L+; TEM, CD8a+CD45RO+CD45RA−CCR7−CD62L−; TEMRA, CD8a+CD45RA+CCR7-CD62L-.
***P<0.001, (one-way ANOVA, corrected with Tukey’s multiple comparisons). (C) The fraction of TN among all CD8a+
T cells in the circulation of age-matched healthy donors (HD; n=39; left), and patients with melanoma (MEL; n=20;
middle) and diffuse large B cell lymphoma (DLBCL; n=17; right) at the time of enrollment to an adoptive
immunotherapy clinical trial. ***P<0.001, ns = not significant (one-way ANOVA, corrected with Tukey’s multiple
comparisons).

Additionally, we discovered that the frequency of Fas- CD8a+ TN in patients is
significantly lower than found in HDs (Figure 4C). The depletion of TN cells likely
reflected the influence of prior immune-stimulating and lymphodepleting therapies in the
cancer patients analyzed6,83,84. Thus, a significant proportion of human T cells used for
ACT express a known death receptor and these cells are transferred into TMEs enriched
in expression of its cognate ligand.

Discussion
In this chapter, we report the results of a pan-cancer analysis which strongly
suggested that a canonical death-inducing ligand, FASLG, is overexpressed within the
majority of human cancer microenvironments. Analysis of the top genes that positively
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correlate with FASLG expression in tumor samples across all histologies show an
association with immune-related genes, especially those associated with lymphocytes and
their subsequent activation. Further interrogation of the patient samples demonstrated that
patient survival largely doesn’t correlate with high or low FASLG expression, with the
exception of a handful of tumor types where FASLG expression does associate
significantly. Examination of patient PBMCs revealed that a significant proportion of
human T cells used for adoptive immunotherapy express Fas, the cognate receptor for
FasL. These intriguing findings indicate that Fas-FasL interactions may play an important
role when Fas+ T cells are adoptively transferred into patients to treat their cancer.
A major stipulation to the patient tumor data demonstrating higher FASLG
expression in cancers over normal tissues is that gene expression data does not reveal
which cells in the tumor microenvironment might express FasL. It certainly is possible
that infiltrating immune cells drive the higher expression of FASLG, which is indicated
by the gene enrichment analysis correlating immune-related pathways with high FASLG
expression. FasL upregulation in the TME, and which cells do so, is also likely to be
histologically dependent, as is indicated by the survival data. This appears to be a
confounding result, as it indicates that the tumor or other suppressor cells potentially
present are not responding to inflammatory signatures with FASLG upregulation, but that
the environment drives FasL expression on the very cells that might respond. Regardless
of the cellular origin of FasL, avoidance of FasL-mediated signaling will likely improve
T cell persistence in vivo, which might have a beneficial impact on tumor outgrowth.
The patient survival data suggest that for the majority of cancer types represented
in the TCGA database, FASLG expression does not consistently influence either
pathogenesis or the natural history of the disease. A critical caveat to interpreting these
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data, however, is that the tumor samples were collected from cancer patients prior to
initiation of any form of therapy. Thus, these data do not provide insight into the
influence of FASLG expression in the TME and responsiveness to a cancer
immunotherapy, including cell-based immunotherapies. Together, these data suggest that
FasL-driven apoptosis of Fas-expressing T cells may impact the anti-tumor efficacy of
ACT.
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CHAPTER 3: BLOCKADE OF FAS SIGNALING IN A T CELL-EXTRINSIC
MANNER

Abstract
Fas is expressed by all memory CD8+ T cell (TMem) subsets despite their
phenotypic and functional heterogeneity. Based on our previous work investigating the
non-apoptotic functions of Fas in naïve CD8+ T cells, we sought to elucidate the roles of
Fas signaling in TMem subsets. Augmenting Fas signaling in T stem cell memory (TSCM)
using an oligomerized form of Fas ligand (FasL) enhanced cellular differentiation,
promoted the loss of IL-2 production and induced apoptosis. Conversely, antibody
blockade (anti-FasL) of Fas signaling in T central memory (TCM) and T effector memory
(TEM) produced phenotypically and functionally less differentiated cells and lead to
greater fold expansion. Using the pmel-1 CD8+ TCR transgenic model, we found that
pmel-1 TMem cultured ex vivo with anti-FasL expanded to higher levels in vivo, acquired
a less exhausted phenotype, and more effectively treated established B16 melanoma
tumors compared to controls. Similarly, TMem expanded with anti-FasL and genetically
engineered with an anti-CD19 chimeric antigen receptor exhibited reduced differentiation
and augmented anti-lymphoma and anti-leukemia activity compared to controls. This
anti-tumor enhancement was found to be related to less differentiated TMem, as anti-FasL
treatment in vitro did not provide anti-apoptotic protection in vivo. Cell-extrinsic Fas
signaling blockade in human CD8+ T cells demonstrated that anti-FasL blocks death but
does not affect differentiation or growth rates. These studies demonstrate that cellextrinsic Fas signaling promotes not only cell death but also TMem differentiation in
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murine CD8+ T cells only, a finding that has implications for the design and execution of
T-cell-based immunotherapies in patients with cancer or infectious disease.

Exogenous Fas signaling induces differentiation and death in memory CD8+ T cells
To investigate the role of Fas signaling in memory CD8+ T cells, we first required
an early memory subset to enable the tracking of less differentiated T cells as they
differentiate from stem cell memory to central memory and finally effector memory. To
generate TSCM in vitro, we stimulated naïve CD44loCD62Lhi CD8+ T cells from young,
healthy B6 female mice in the presence of the GSK3β inhibitor TWS119, a Wnt signaling
agonist that enables the generation of large numbers of TSCM in cell cultures85-87 (Figure
5A).
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Figure 5. Experimental setup to test exogenous FasL signaling in TSCM.
A) Schematic of experimental design. Naïve-isolated CD8a+ T cells were stimulated with aCD3 (2 mg/mL), aCD28 (1
mg mL-1) and IL-2 (5 ng mL-1) in the presence of GSK3β inhibitor TWS119 (5 µM mL-1) for 6d, the sort-purified for
CD8a+ CD44loCD62Lhi TSCM. TSCM were then re-stimulated without TWS119 in the presence of increasing
concentrations of lz-FasL (0-10 ng mL-1). B) Representative FACS plots demonstrating purity of TSCM sort and high Fas
expression of the sorted CD44loCD62Lhi CD8a+ T cells.

After 5-6d in culture TSCM were FACS-purified as marked by CD44loCD62Lhi expression.
Flow analysis of the isolated TSCM showed that they co-express high levels of Fas in
comparison to non-stimulated TN, indicating that these cells were truly activated TSCM
and not unstimulated TN still in culture (Figure 5B).
These cells were then re-stimulated in the presence of increasing doses of
oligomerized FasL (lz-FasL) to induce signaling through the Fas receptor. This lz-FasL is
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composed of the extracellular region of FasL linked to an isoleucine zipper, which
enables FasL to interlock together to form oligomers, which supports better signaling
through the Fas receptor88. After 6d in culture, we found that re-stimulation of TSCM in
the presence of lz-FasL resulted in lost CD62L expression and resulted in more TEM in
comparison to TSCM re-stimulated alone (Figure 6A and B).
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Figure 6. Exogenous FasL causes differentiation and death in TSCM.
A) Representative FACS plots of differentiation state (left) and IL-2 production (right) of live, CD8a+ cells grown at 0
and 10 ng mL-1 lz-FasL. B) Bar plot of memory subset composition of live, CD8a+ cells in culture grown at 0 and 10 ng
mL-1 lz-FasL. C) Total intracellular IL-2 production in live, CD8a+ cells grown in 0 and 10 ng mL-1 lz-FasL, measured by
intracellular cytokine staining. D) Representative FACS plots of cell viability of live singlet cells stained with Annexin V
and PI. E) Total number of live CD8a+ cells 6d after re-stimulation in the presence of indicated doses of lz-FasL.
**p<0.01, *** p<0.001, ****p<0.0001 (one-way ANOVA).

If Fas signaling increases the percentage of cells matching the TEM phenotype, we
expected this would result in a smaller percentage of the total population able to produce
IL-2, a cytokine produced by less differentiated subsets like TSCM and TCM89. We
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stimulated cells cultured with or without 10 ng/mL of lz-FasL and looked at intracellular
IL-2 production. Consistent with the more differentiated phenotype (CD62Llo) observed,
we saw that the cells cultured with lz-FasL had less IL-2 production compared to cells
grown without exogenous Fas signaling (Figure 6A and C). This functional finding,
together with the loss of CD62L expression, implies that Fas signaling drives cells to
more terminally differentiated TEM subset.
As expected, we also found higher levels of early apoptotic and necrotic cells in
the cultures grown with the highest concentration of lz-FasL as shown by Annexin V and
PI staining (Figure 6D). However, we found that FasL-mediated differentiation occurred
at concentrations too low to induce apoptosis67, as total cell number at the end of the
culture period was unaffected until the highest concentrations of lz-FasL was reached
(Figure 6E). One could hypothesize that the differences in phenotype and function in the
lz-FasL cultures could be due to preferential death in less differentiated memory subsets
like TSCM or TCM. However, we have previously shown that TEM are likeliest to undergo
Fas-mediated apoptosis in the presence of TCR and Fas signaling67, indicating it is
unlikely that Fas signaling causes preferential loss of TCM in the high concentration lzFasL cultures. Thus, increasing the concentration of lz-FasL suggests that before
inducing death, Fas signaling can also mediate cell differentiation.

Cell-extrinsic blockade of Fas signaling prevents memory CD8+ T cell
differentiation
Since more Fas signaling seems to drive cells to a more differentiated state, we
hypothesized that blockade of Fas signaling would preserve CD62L expression and IL-2
production in memory CD8+ T cells. To test this hypothesis, we vaccinated pmel-1 TCR
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transgenic mice with 2x107 p.f.u. of recombinant vaccinia virus expressing human gp100
protein (rVV-hgp100) to induce expansion and differentiation of pmel-1 T cells in vivo
(Figure 7A).

Figure 7. Blockade of Fas signaling in memory T cells prevents TCM differentiation.
A) Schematic demonstrating experimental design. Pmel-1 TCR transgenic mice were vaccinated with 2x107 p.f.u. of
vaccinia virus expressing human gp100 protein (rVV-hgp100). 30d later, CD8a+ CD44+CD62L+ TCM or CD44+CD62L- TEM
cells were FACS sort-purified then stimulated for 6d as in Figure 5 in the presence of blocking aFasL (10 μg mL-1) or
control IgG1 antibody. B) Representative FACS plots (left) and memory subset composition (right) of live, CD8a+ TCM
cells in each culture condition of differentiation after 6d in each culture condition. C) Relative fold expansion of live,
CD8a+ TCM cells compared to IgG1 control. D, E) Representative FACS plots (D) and total production (E) of intracellular
IFNg and IL-2 production in each culture condition. Representative plots from 3 replicates. ***p<0.001, ****p<0.0001
(unpaired Student’s t-test).

After 30d, we isolated pmel-1 CD8+ T cells from the vaccinated mice, and sort-purified
for CD62L+CD44+ TCM and stimulated them in vitro for 6d in the presence of a control
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IgG1antibody or a blocking non-agonistic FasL antibody90. Cells cultured without Fas
signaling blockade had much higher expression of CD62L compared to the controltreated cells (Figure 7B). Blockade of Fas signaling also resulted in much larger fold
expansion of CD62L+CD44+ cells as compared to the control treated cells (Figure 7C).
Due to the higher number of TCM seen in the anti-FasL treated culture, we
hypothesized that this population would be able to produce more IL-2 and less IFNγ
compared to the controls. As expected, there was a corresponding increase in the amount
of IL-2 production in the culture where Fas signaling was prevented (Figure 7D and E).
However, we did not routinely uncover less IFNg production in the anti-FasL treated
cells, often seeing a trend towards more IFNg production instead (Figure 7D and E).
We next wished to understand how Fas signaling blockade could affect TEM
differentiation. To do so, we stimulated vaccine-induced, sort-purified TEM in vitro in the
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presence of anti-FasL antibody or control antibody (Figure 8A), then analyzed
phenotypic and functional characteristics after 6d in culture.

Figure 8. Blockade of Fas signaling in memory T cells prevents TEM differentiation.
A) Schematic demonstrating experimental design. Pmel-1 TCR transgenic mice were vaccinated with 2x107 p.f.u. of
rVV-hgp100. 30d later, CD8a+ CD44+CD62L- TEM cells were FACS sort-purified then stimulated for 6d as in Figure 5 in
the presence of blocking aFasL (10 μg mL-1) or control IgG1 antibody. B) Representative FACS plots (left) and memory
subset composition (right) of live, CD8a+ TEM cells in each culture condition of differentiation after 6d in each culture
condition. C) Relative fold expansion of live, CD8a+ TEM cells compared to IgG1 control. D) Expression of differentiation
marker CD27 and exhaustion markers PD-1 and 2B4 after 6d in each culture condition. Representative plots from 3
replicates. **p<0.01, ****p<0.0001 (unpaired Student’s t-test).

As expected with CD62L-CD44+ TEM cells, we could not see further differentiation of the
TEM by CD62L or CD44 expression as the cells had already lost CD62L expression
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(Figure 8B). However, we could see that cells grown in the presence of anti-FasL had
greater fold expansion compared to TEM grown with control antibody (Figure 8C).
Because differentiation of cultured TEM could not be analyzed using CD62L
expression, we turned to other phenotypic markers of differentiation, including
expression of costimulatory molecule CD27 and exhaustion markers PD-1 and 2B4. After
6d in culture, we found that there were higher levels of CD27 expression on TEM
incubated with anti-FasL, indicating a less differentiated phenotype of the late effector T
cells (Figure 8D). Additionally, the anti-FasL treated cells had lower levels of PD-1 and
2B4, indicating that these cells were prevented from reaching the same exhaustion levels
as those cells incubated in the presence of control antibody.
Taken together, these data indicate that blockade of Fas signaling during the in
vitro culture of TCM and TEM can preserve a less differentiated phenotype and functional
capability of T cells. These characteristics of higher IL-2 production and greater cell
numbers are associated with better control of tumor growth when these cells are used for
adoptive cell transfer in murine tumor models65,85,91, indicating that anti-FasL treatment
of T cells could provide a therapeutic benefit.

Anti-FasL treatment in vitro promotes in vivo persistence and anti-tumor function
Our work demonstrated that cell-extrinsic Fas signaling blockade was capable of
preventing death and differentiation during in vitro culture of memory CD8+ T cells,
resulting in higher numbers of less differentiated cells. However, it is not clear what
effect anti-FasL treatment would have on T cells when used as a therapeutic product. To
determine if anti-FasL ex vivo treatment confers a benefit to in vivo T cell function and
persistence, we stimulated congenically marked pmel-1 CD8+ T cells for 6d in vitro, then
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re-stimulated the T cells in the presence of anti-FasL or control IgG1 antibody for another
6d (Figure 9A).

Figure 9. In vitro blockade of FasL promotes T cell persistence in vivo.
A) Schematic of experimental design. Congenically marked pmel-1 splenocytes were stimulated with hgp100 peptide
(1 mM mL-1) and IL-2 (5 ng mL-1) for 6d, then re-stimulated for 6d as in Figure 5 in the presence of blocking aFasL (10
μg mL-1) or control IgG1 antibody. 7.5x105 cells from each group were injected into sublethally irradiated (6 Gy) B6
mice, then vaccinated with 2x107 p.f.u. of rVV-hgp100. Six doses of IL-2 were given twice daily for 3d after cell
injection. Mice were sacrificed on indicated days and splenocytes were analyzed via flow cytometry. B) Total number
(left) and relative fold expansion (right; compared to IgG control) of live, Thy1.1+ CD8a+ Vb13+ cells found in spleen on
indicated days. C) Uveitis scores. Eyes were harvested on day 14, fixed, stained with hematoxylin and eosin and
graded for ocular inflammation on a scale of 0-4 in a blinded manner. D) Representative FACS plots of live Thy1.1+
CD8a+ Vb13+ cells stained with indicated antibodies. E) Percentage of live, Thy1.1+ CD8a+ Vb13+ cells expressing CD62L
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(left), KLRG-1 (middle), or CD27 (right) for each condition. Representative plots from two independent experiments.
*p<0.05, **p<0.01, *** p<0.001, ****p<0.0001 (unpaired Student’s t-test).

We then infused 7.5x105 of either anti-FasL or IgG1-treated cells into sublethally
irradiated B6 mice along with 2x107 p.f.u. of rVV-hgp100. Mice also received IL-2 twice
daily for 3d, then were sacrificed on the indicated days to study T cell persistence and
phenotype. We consistently found that anti-FasL-treated pmel-1 CD8+ T cells expanded
to greater numbers in vaccinated mice compared to mice receiving IgG1-treated T cells,
resulting in a more robust fold expansion (Figure 9B) over the same cells.
Additionally, analysis of an on-target effect of adoptively transferred pmel-1 T
cells showed that mice treated with anti-FasL treated cells had higher levels of uveitis,
indicating that anti-FasL treated pmel-1 T cells were attacking gp100 expressing
melanocytes in the eye at greater levels in comparison to mice given IgG1-treated cells or
to untreated mice (Figure 9C). When we analyzed the phenotype of the cells, we found
that anti-FasL treated cells acquired less KLRG-1 over time and maintained higher levels
of CD62L and CD27 in comparison to IgG1-treated T cells (Figure 9D and E). Thus,
despite no anti-FasL treatment occurring in vivo, Fas signaling blockade during ex vivo
culturing of T cells promotes greater in vivo persistence of less differentiated T cells
during a robust in vivo stimulation.
Due to the greater fold expansion demonstrated in vivo, we next sought to
determine the anti-tumor capabilities of anti-FasL-treated T cells genetically engineered
to express a CAR targeting CD19+ tumor cells. We first chose a syngeneic model of
murine lymphoma, 38c13, in C3H mice. We re-stimulated 6d old TMem in the presence of
anti-FasL or control antibody, then transduced the cells with a retroviral construct
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encoding a second generation anti-CD19 28z CAR92 (Figure 10A).
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Figure 10. Anti-FasL treated cells show greater anti-tumor efficacy.
A) Experimental design of experiment. B) In vitro-derived memory CD8a+ T cells were re-stimulated as described in
Fig. 4. During re-stimulation cells were transduced with a chimeric antigen receptor (CAR) derived from anti-CD19
antibody 1D3. Five days later 6x106 anti-CD19 CAR+, IgG- or anti-FasL-treated cells were injected into sublethally
irradiated (5 Gy) C3H mice bearing subcutaneous, 4d old CD19+ 38c13 lymphoma. 3 doses of IL-2 were given once
daily. B) Tumor size and C) survival of 38c13 tumor-bearing mice. D) Experimental schema for the generation and
infusion of B6 CD8a+ T cells engineered to express anti-CD19-CAR+ and grown with IgG1 control or anti-FasL
antibodies. Five days later 1x106 anti-CD19 CAR+, IgG- or anti-FasL-treated cells were injected into sublethally
irradiated (5 Gy) B6 mice bearing 4d old E2a-PBX leukemia. 3 doses of IL-2 were given once daily. E) Survival of E2APBX tumor-bearing mice. Tumors were measured in blinded fashion by another investigator. B) **p<0.01, ns = nonsignificant (Wilcoxon rank sum test). C, E) *p<0.05, **p<0.01, (log-rank (Mantel-Cox) test).

After 5d in culture, 6x106 anti-CD19 CAR+ cells were infused into sublethally irradiated
C3H mice bearing 4d old subcutaneous lymphoma 38c13. Anti-FasL-treated anti-CD19
CAR+ cells were able to control lymphoma growth significantly longer than IgG1
control-treated cells (Figure 10B), resulting in significantly longer overall survival of the
lymphoma-bearing mice (Figure 10C).
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We also tested anti-FasL T cell treatment in a recently developed B6 syngeneic
model of CD19+ B-ALL93 to determine if anti-FasL treated cells could provide greater
protection against a liquid cancer. We grew B6 CD8a+ T cells in the presence of IgG1 or
anti-FasL antibody and transduced the T cells to express anti-CD19 CAR, then infused
them into sublethally irradiated B6 mice bearing 4d old E2a-PBX leukemia (Figure 10D).
Again, we found that anti-FasL-treated CAR+ T cells were able to mediate greater
survival of leukemia-bearing mice in comparison to mice given IgG1-treated CAR+ cells
(Figure 10E).
In a third model, we grew pmel-1 T cells as described in Figure 9A, then infused
equal numbers of IgG1- or anti-FasL-treated cells into sublethally irradiated B6 mice

33

bearing 10d old B16 melanoma (Figure 11A).

Figure 11. Differentiation accounts for improved anti-tumor efficacy.
A) Schematic of experimental design. Congenically marked pmel-1 splenocytes were grown as in Figure 9. 2x105 cells
from each condition were injected into sublethally irradiated (6 Gy) B6 mice that had B16 melanoma tumors
subcutaneously injected 10d previously. 2x107 p.f.u. of rVV-hgp100 were injected with the cells followed by 6 doses of
IL-2 given twice daily. Tumor size (B) and survival (C) of B16 tumor-bearing mice. D) Representative FACS plots
demonstrating the purity of sorted CD62L+CD44+Thy1.1+ TCM-like pmel-1 T cells modified grown with IgG1 or anti-FasL
prior to infusion. All treated mice received sublethal irradiation (6 Gy) prior to cell infusion followed by 3d of i.p. IL-2.
(E) Tumor regression of mice bearing 10d established B16 melanoma tumors who were untreated or received 5 x 105
of sort-purified TCM-like Thy1.1+ modified cells. Tumors were measured in blinded fashion by another investigator. B,
E) *p<0.05 **p<0.01, ns = non-significant (Wilcoxon rank sum test). C) **p<0.01, (log-rank (Mantel-Cox) test).
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In this vaccine-dependent model, we additionally infused 2x107 p.f.u. rVV-hgp100 and
gave IL-2 twice daily for 3d. In this model we also found that anti-FasL treated cells were
able to control tumor growth in a superior manner (Figure 11B), leading to longer animal
survival in comparison to mice treated with IgG1-treated pmel-1 T cells (Figure 11C).
As seen in Figures 7 and 8, T cells grown with anti-FasL antibody are less
differentiated after 6d in culture. Additionally, we previously reported that in vitro
expansion of a mix of TN and TMem pmel-1 T cells grown with FasL antibody blockade
preserved a population of less differentiated TCM relative to IgG1 control antibody-treated
cells, and these cells conferred superior B16 tumor regression compared with IgG1treated control T cells67. However, both the anti-FasL treated TN + TMem mix and those
shown in Figure 11B and C were less differentiated at the time of cell infusion than the
IgG1-treated cells in these experiments. We and others have previously shown that less
differentiated T cells confers superior anti-tumor efficacy compared with more mature T
cells47,91,94. We therefore sought to test if in vitro FasL blockade benefits the in vivo antitumor efficacy of adoptively transferred T cells when differentiation status is normalized.
We FACS-sorted TCM-like CD62L+ cells following in vitro expansion in the presence of
anti-FasL or IgG1 control (Figure 11D). After infusion into B16 tumor-bearing mice, we
discovered that the in vivo benefit following anti-FasL blockade is lost when cells are
normalized for a TCM phenotype (Figure 11E). These data suggest that the anti-tumor
benefit of cell-extrinsic, antibody-based blockade of FasL-Fas interactions in vitro was
attributable to restraining T cell differentiation prior to adoptive transfer.
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Blockade of Fas signaling in human CD8+ T cells prevents apoptosis but not
differentiation
The repeatable and robust prevention of Fas-mediated death and differentiation
that we demonstrated above prompted us to determine if cell-extrinsic Fas signaling
blockade could provide the same benefits in human CD8+ T cells. CD8+ T cells were
isolated from HD PBMC and stimulated with anti-CD3/CD28 in the presence of IL-2 and
either anti-human anti-FasL or a control IgG1 antibody. When these cells were cultured
in the presence of lz-FasL, we found that anti-FasL treated cells prevented FasL-mediated
apoptosis and led to greater cell viability (Figure 12A).
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Figure 12. Blockade of Fas signaling blocks human T cell death but not differentiation.
CD8+ T cells were isolated from PBMC from three healthy human donors (HD) and stimulated with anti-CD3 (2 µg mL1) and anti-CD28 (1 µg mL-1) in the presence of anti-FasL (NOK-1) and IL-2 (20 ng mL-1) for 11d. A) Summary bar graph
of relative T cell viability (relative to no anti-FasL) following overnight culture in the presence of lz-FasL (100 ng mL-1)
for 24h. B) Relative fold expansion of live CD8+ T cells from 3 donors grown with IgG or anti-FasL antibodies. C, D)
Representative FACS plots CD27 and CD62L staining (C) and summary bar graph of CD62L expression of live CD8+ T
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cells. Data shown is representative of 5 independently performed experiments and is displayed as mean ± SEM with n
= 3 per condition. ****P<0.0001, ns = not significant (two-way ANOVA).

However, we did not see any increase in fold expansion in anti-FasL-treated human CD8+
T cell cultures compared to IgG1-treated control cells (Figure 12B). Additionally, we did
not observe an impact on differentiation when human CD8+ T cells were grown in the
presence of anti-FasL, finding that there was no significant difference in CD62L or CD27
expression between anti-FasL or IgG1 treated groups (Figure 12C and D). These data
indicate that a cell-extrinsic Fas signaling blockade has no impact on in vitro fold
expansion or differentiation in human CD8+ T cell cultures.

Discussion
The above studies demonstrate that Fas signaling in murine T cells promotes both
differentiation in memory CD8+ T cells as well as programmed cell death. This
differentiation drives TSCM to a TEM-like phenotype and results in less IL-2 production. In
our loss-of-function studies, we found that cell-extrinsic Fas signaling blockade utilizing
anti-FasL antibody could prevent Fas-mediated differentiation and apoptosis, resulting in
less differentiated T cells that expanded to greater levels than control-treated T cells.
When these T cells were adoptively transferred in vivo, we found that anti-FasL treated
cells persisted at higher levels and maintained more CD62L expression, and this resulted
in superior anti-tumor efficacy in three different syngeneic tumor models.
Testing of Fas signaling blockade in human T cells found that while anti-FasL
blockade could prevent FasL-mediated apoptosis, human CD8+ T cells grew and
differentiated at the same rate as control antibody treated cells. Unexpectedly, the robust
effects of cell-extrinsic Fas signaling blockade we observed in murine T cells did not
translate to human T cell culture. These results were surprising, given that we had
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previously found that culturing human T cells in the presence of exogenous lz-FasL
drove a robust loss of CD27 and CCR7 concordant with the increasing concentration of
lz-FasL in the culture67. It is possible that anti-FasL treatment during ex vivo T cell
culture of human CD8+ T cells does not impact differentiation state due to the differential
kinetics of upregulation of FasL on human T cells in comparison to murine CD8+ T cells.
It is also possible that Fas-mediated differentiation does not occur in human CD8+ T cell
cultures unless cells are re-stimulated multiple times.
Additionally, our assays do not discern if the greater percentage of murine TCM
observed in the cultures was due to preservation of cells that would have undergone Fasinduced death or if Fas-mediated co-stimulation was blocked, or if it was due to a
combination of both factors. Future experiments to address this could include death
analyses in cultures where Fas signaling is blocked or augmented at various time points
while cells are grown in varying densities to encourage or discourage cell-cell
interactions.
Exploring the role of Fas signaling beyond programmed cell death offers a way to
explain expression of a death receptor on all memory CD8+ T cell subsets: one could
imagine that Fas signaling drives memory T cells quickly into proliferation and
production of effector molecules in response to intracellular pathogens. This faster and
stronger response could, in turn, protect the host from illness. Better understanding this
pathway could allow manipulation of Fas signaling during antigen response,
preferentially preserving less-differentiated memory T cells and growing more effective
T cells for adoptive immunotherapy.
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CHAPTER 4: BLOCKADE OF FAS SIGNALING IN A T CELL-INTRINSIC
MANNER
Abstract
Adoptive T cell therapy for the treatment of cancer has shown impressive
response rates and regressions, but these successes occur in only a handful of
malignancies. Understanding ways in which T cell function and longevity can be
enhanced might improve responses in hard-to-treat metastatic epithelial cancers. We have
previously shown that cell-extrinsic blockade of the death receptor, Fas, prevented death
and differentiation in murine CD8+ T cells, but Fas blockade in human CD8+ T cells
showed no effect on differentiation or cell expansion. We hypothesized that a cognate
Fas-FasL interaction between the tumor-bearing host and transferred T cells might limit T
cell expansion, persistence and anti-tumor efficacy. We found that Fas-competent mouse
and human T cells genetically engineered with Fas variants, containing point mutations
or truncations within the death domain and blocking FADD recruitment, function in a
dominant negative fashion (Fas DNR) to rescue modified T cells from FasL-induced
apoptosis. Following infusion in vivo, Fas DNR-engineered T cells expanded and
persisted at higher frequencies, leading to better anti-tumor efficacy and longer animal
survival in both a solid and hematologic cancer model. In long-term experiments, T cells
overexpressing Fas DNR did not clonally expand or result in acquired autoimmune
lymphoproliferative syndrome. Thus, a built-in Fas signaling block can shield T cells
from the negative influence of FasL, presenting a potentially universal strategy to
enhance ACT efficacy across a broad range of human malignancies.

Creation and testing of dominant negative Fas receptor constructs
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Our findings indicated that patient-derived T cells used for adoptive
immunotherapy are skewed towards Fas-expressing subsets, which are subsequently
transferred into FASLG-enriched TMEs. Based on these data, we investigated whether
disruption of Fas signaling within adoptively transferred T cells might prevent their
apoptosis and improve in vivo persistence. In addition to triggering T cell apoptosis, FasL
is also an essential effector molecule for T cell-mediated tumor killing95. Further,
systemic administration of either an anti-FasL antibody or Fas-Fc fusion protein might
induce toxicities, including development of a lymphoproliferative syndrome and
accumulation of an abnormal population of double-negative (DN) CD3+B220+CD4-CD8TCRa/b+ T cells96,97. For these reasons, we pursued a cell-intrinsic genetic engineering
strategy to disable Fas signaling only within tumor-reactive T cells to maintain anti-tumor
potency and minimize the risk of systemic toxicity.
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Physiologically, FasL initiates apoptotic signaling by first inducing
oligomerization of Fas receptors into trimers or larger oligomers at the cell membrane
(Figure 13A)98.
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Figure 13. Fas signaling and design of retrovirally-encoded Fas DNR constructs and controls in mouse CD8+ T cells.
(A) Schematic representation of physiologic Fas signaling and the design of two murine Fas dominant negative
receptors (DNRs). Retroviral-encoded Fas DNRs were designed to prevent recruitment of Fas-associated protein with
death domain (FADD) either by (i) substitution of an asparagine for an isoleucine residue at position 246 of the death
domain (DD; FasI246N), or (ii) truncation of the majority of the intracellular death domain (Fas∆DD). Wildtype Fas (FasWT)
and an empty vector were used as controls. Receptors were cloned into a bicistronic vector containing a Thy1.1
reporter. EC, extracellular domain; TM, transmembrane domain; T2A, thosea asigna virus 2A self-cleaving peptide. (B)
Schematic overview of the designs for retroviral constructs encoding murine wildtype (WT) Fas or mutant versions of
Fas impaired in their ability to bind the intracellular adapter molecule Fas-associated via death domain. WT Fas,
FasI246N, or Fas∆DD were cloned into an MSGV1 expression vector in front of a T2A cleavage site and the Thy1.1
reporter gene. An empty vector containing only the Thy1.1 reporter gene (Empty) was used as a negative control.
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Fas oligomers recruit the intracellular adapter molecule Fas-associated via death domain
(FADD) through homotypic death domains (DD) present in each molecule99,100.
Aggregation of FADD recruits the cysteine-aspartic acid protease pro-Caspase 8101
through homologous death effector domains in each molecule, forming the death
inducing signaling complex that can initiate the apoptotic signaling cascade102. Based on
this mechanism of action, we hypothesized that overexpression of mutated Fas variants
genetically altered to prevent FADD binding would function as dominant negative
receptors (DNRs) when expressed in Fas-competent wild type (WT) T cells used for
adoptive immunotherapy. Presently, virus-based constructs are the most commonly used
methods to stably modify human T cells for clinical application103. Therefore, we created
a series of retroviral constructs encoding the murine Fas sequence in which either an
asparagine residue was substituted for an isoleucine at position 246 of the DD (FasI246N; a
naturally occurring mutant of murine Fas which is unable to bind FADD104), or a Fas
mutant in which the majority of the intracellular DD was truncated (del aa222-306;
FasDDD) to prevent FADD binding (Figure 13A and B). As controls, we generated both an
empty vector construct as well as a construct encoding the complete WT sequence of Fas
(FasWT; Figure 13B). To identify transduced cells, all vectors contained a Thy1.1 reporter
separated from Fas using a T2A “self-cleavage” sequence.
T cells were isolated from Fas-competent WT mice, activated by anti-CD3/CD28
antibodies in the presence of IL-2, and transduced with the empty, FasWT, FasI246N, or
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FasDDD constructs (Figure 14A).
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Figure 14. Expression of Fas DNR constructs and controls in mouse CD8+ T cells.
(A) Experimental timeline for the stimulation, retroviral transduction, expansion, and testing of lz-FasL mediated
apoptosis of WT CD8a+ T cells modified with FasI246N, Fas∆DD, FasWT, or an empty vector control. (B) Representative
FACS plots and summary bar graphs of (C) Thy1.1 and (D) Fas expression 4d following retroviral transduction of Fasdeficient lpr/lpr or WT CD8a+ T cells. The percentage of gated Thy1.1+ or Fas+ cells is shown in black, MFI of Thy1.1+ or
Fas+ cells is shown in red on flow plots (C). Fold change in Fas MFI over endogenous, WT Fas expression in WT, Emptytransduced cells is shown in red in (D). Data in (C) and (D) are displayed as mean ± SEM with n=3 per condition and is
representative of 12 independent experiments.

Phenotypic analysis 6d following activation and transduction revealed high transduction
efficiencies for all constructs as measured by Thy1.1 reporter expression (Figure 14B and
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C). Notably, ectopic Fas expression was measurably higher than endogenous levels of
Fas expression for constructs containing either the WT (6.8-fold higher Fas MFI) or
mutant Fas variants (43-fold and 98-fold higher Fas MFI for FasI246N or FasDDD,
respectively; Figure 14D).
After 6d in culture, transduced T cells were stimulated with recombinant FasL
molecules oligomerized through a leucine zipper domain (lz-FasL) to mimic the function
of membrane-bound FasL88 or left untreated as controls. In the absence of lz-FasL, T
cells transduced with each of the constructs remained similarly viable (Figure 15A).
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However, following exposure to lz-FasL, a significant proportion of Thy1.1+ T cells
transduced either with the empty vector control or FasWT converted to an apoptotic
Annexin V+PI+ population (Figure 15A and B; P<0.001). Interestingly, overexpression of
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FasWT consistently resulted in higher levels of apoptosis relative to empty vectortransduced T cells, indicating that expression of Fas above physiologic levels sensitized T
cells to FasL-mediated cell death. By contrast, T cells transduced either with the FasI246N
or FasDDD vectors were almost completely protected from lz-FasL-induced apoptosis.
Among pools of T cells transduced with FasI246N or FasDDD, protection from
apoptosis was most evident in the Thy1.1+ populations. However, we also noted a relative
increase in the viability of non-transduced Thy1.1- T cells in cultures where cells were
transduced with FasI246N or FasDDD (Figure 16).
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Figure 16 Fas DNRs can protect non-transduced cells from FasL-mediated apoptosis.
Summary bar graph showing the relative frequency of cell viability of non-transduced and transduced T cells after 20h
following exposure to lz-FasL (100 ng/mL). Results shown after gating on live CD8 + lymphocytes, and viability shown
relative to the media for each transduction condition. Data shown is representative of 3 independently performed
experiments and is displayed as mean ± SEM with n = 3 per condition. ****P<0.0001, ns = not significant (one-way
ANOVA, corrected with Tukey’s multiple comparisons).
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This suggests that FasI246N and FasDDD may also protect neighboring T cells from
apoptosis, likely functioning as a “sink” for local FasL.
In T cells modified with FasI246N, we found neither functional nor genetic
evidence of reversion to the WT sequence. We measured selective enrichment for T cells
modified with FasI246N compared with FasWT following serial in vitro re-stimulation with
anti-CD3/CD28 antibodies, indicating that the DNR remained functionally intact over
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time (Figure 17A and B).
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maintains the A-T-C sequence encoding the isoleucine at amino acid position 246, whereas the FasI246N sequence is AA-C, encoding an asparagine at amino acid position 246 in the introduced Fas DNR construct.

47

Further, Sanger sequencing of serially re-stimulated, FasI246N-transduced T cells showed
no evidence of reversion of the I246N point mutation to the WT Fas sequence (Figure
17C and D). Thus, overexpression of Fas variants disabled their ability to bind FADD
function in a dominant negative manner to prevent FasL-mediated apoptosis in WT T
cells.
Finally, we sought to determine whether the Fas DNRs afforded protection from
other potential apoptosis-inducing stimuli which an adoptively transferred T cell might
encounter in vivo. These include TCR re-stimulation-induced cell death (RICD), cytokine
withdrawal, and proximity to tumor cells. For these assays, we utilized pmel-1 T cells
and B16 melanoma engineered to express human gp100. Although B16 cells did not
express FasL at rest, FasL expression was measurably upregulated following incubation
with IFNg (Figure 18).
MHC Class I

FasL
= IFNg

Count

= vehicle

H-2Db

FasL

Figure 18 IFNg upregulates FasL on surface of B16 tumor cells.
B16 cells were treated with vehicle (PBS) or IFNg (100 ng mL-1) for 24 hours, then analyzed for surface expression of
MHC Class I (H-2Db; left panel) or FasL (right panel) by flow cytometry.
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We found that pmel-1 T cells transduced with FasI246N or FasDDD provided equal
protection from apoptosis triggered by either lz-FasL or tumor co-culture (Figure 19).
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Figure 19. T cells engineered with Fas DNRs prevent apoptosis from various stimuli.
Summary bar graph showing the relative frequency of cell viability of transduced T cells after 20h following exposure
to lz-FasL (100 ng/mL). Results are shown after gating on transduced Thy1.1+ cells, and viability is shown relative to
Fas∆DD. Data shown is representative of 10 independently performed experiments and is displayed as mean ± SEM
with n = 3 per condition. *P<0.05 **P<0.01 ****P<0.0001, ns = not significant (one-way ANOVA, corrected with
Tukey’s multiple comparisons).

By contrast, T cells transduced with FasDDD resulted in significantly greater cell viability
following RICD induction through anti-CD3/CD28 re-stimulation or acute cytokine
withdrawal relative to cells modified with FasI246N. These findings are potentially
attributable to the ability of the FasI246N variant to continue to bind to FADD with
reduced efficiency under certain conditions105. We therefore subsequently focused
exclusively on the FasDDD DNR for all in vivo experiments given its superior functional
attributes. This permitted us to more clearly determine the influence of removing Fas
signaling on the in vivo function of adoptively transferred T cells.
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Adoptive transfer of T cells engineered with Fas DNR results in superior persistence
Having established that modification with FasDDD prevented T cell apoptosis in
vitro across a diverse range of apoptosis-inducing stimuli, we sought next to determine
whether engineering with this Fas DNR resulted in superior in vivo persistence following
adoptive transfer. We therefore adoptively transferred congenically marked, genemodified pmel-1 T cells into sublethally irradiated Thy1.1- B6 mice to induce
homeostatic proliferation, just as was done in our tumor treatment experiments. T cells
transduced with FasDDD or empty vector control were identified by expression of the
Thy1.1 reporter gene. To measure T cell proliferation, we co-stained for the cellular
proliferation marker Ki67. One day after transfer, FasDDD- and empty vector-modified
pmel-1 T cells engrafted at similar levels and almost uniformly expressed Ki67 (Figure
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Figure 20. Enhanced persistence and survivability of Fas DNR-engineered T cells in vivo.
Transduced Ly5.1+ d11 pmel-1 CD8a+ T cells were generated as described in Figure 17C, then 5x105 cells from each
group were injected into sublethally irradiated (6 Gy), Ly5.2+ B6 mice. Six doses of IL-2 were given once daily for 3d
after cell injection. Mice were sacrificed on indicated days and splenocytes were analyzed via flow cytometry for
homeostatic expansion of Ly5.1+ pmel-1 CD8a+ T cells. (A) Total number of live, Ly5.1+ CD8a+ Vb13+ cells transduced
with the Empty or Fas∆DD constructs. (B) Relative fold expansion of Fas∆DD compared to Empty construct found in
spleen on indicated days. (C) Percentage of live, Ly5.1+ CD8a+ Vb13+ cells expressing Ki67 for each condition.
Representative plots from two independent experiments. Data is displayed as mean ± SEM with n = 3 per condition
displayed and is representative of 3 independent experiments. *P<0.05, ns = not significant (Wilcoxon rank sum test).
(D) Experimental schema for the generation and co-infusion of congenically distinguishable, WT pmel-1 CD8a+ T cells
engineered with Fas∆DD DNR (Ly5.1+Thy1.1+) or an empty vector control (Ly5.1-Thy1.1+). Transduced T cells were
enriched with an anti-Thy1.1 microbead prior to recombination in a ~1:1 mixture and a total of 8e6 T cells were
infused i.v. into sublethally irradiated (6 Gy) Thy1.1-Ly5.1- mice bearing 10d established B16 melanoma tumors.
Recipient mice received IL-2 by daily i.p. injection for 3d and the spleens and tumors were harvested for analysis on
d7. (E) Relative persistence of Fas∆DD DNR-modified to empty vector-modified T cells in the spleens and tumors of
recipient mice. Results displayed after gating on live, CD8a+Thy1.1+ lymphocytes and are representative of two
independent experiments, each with n=5-8 mice. ***P<0.001 (unpaired 2-tailed Student’s t test).

Beginning within 3d of transfer, we measured a multi-log expansion of both populations
of modified cells. However, at the peak of expansion, we noted a ~50-fold greater
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increase in the numbers of FasDDD-modified T cells relative to control modified cells.
This in turn led to a >10-fold higher level of persistence of Fas DNR-modified T cells at
30d (Figure 20A and B). Over time, we measured a comparable reduction in Ki67
expression on both empty- and FasDDD-engineered T cell populations (Figure 20C) which
correlated with reconstitution of the host’s endogenous T cell compartment. These data
suggested that the in vivo proliferation was comparable between the two engineered T
cell populations. However, Fas DNR-modified T cells demonstrated superior overall
expansion and intermediate-term persistence, likely through a reduction in apoptosis.
We next sought to ascertain if genetic modification with the Fas DNR resulted in
superior T cell persistence within the TME. To ensure that modified T cells were exposed
to the same microenvironmental factors within any given tumor, we performed a coinfusion experiment. Congenically distinguishable pmel-1 CD8a+ T cells were obtained
from either a Ly5.1-/Thy1.1- or Ly5.1+/Thy1.1- background. Cells were transduced with
the FasDDD DNR or a Thy1.1-expressing empty vector control, respectively. Transduced
T cells were subsequently purified using anti-Thy1.1 microbeads, recombined in a
roughly 1:1 ratio, then co-infused into sublethally irradiated Ly5.1-/Thy1.1- mice bearing
10d established B16 melanoma tumors (Figure 20D). As is currently done in many ACT
clinical trials for solid tumors, treated mice received a limited course of IL-2 following
transfer19,20,62,106,107. Seven days following infusion, both spleens and tumors of recipient
mice were harvested and analyzed for the presence of adoptively transferred, genetically
modified, Thy1.1+ pmel-1 T cells. We consistently found significant enrichment of
Ly5.1+ Thy1.1+ FasDDD-modified T cells relative to Ly5.1- Thy1.1+ empty vectormodified T cells in both the spleen and tumor of recipient mice (Figure 20E; P<0.001).
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Together, these results indicated that genetic engineering with a Fas DNR enhanced T
cell persistence in vivo in both the spleen and TME following adoptive cell transfer.

ACT of Fas DNR-modified T cells does not result in an acquired ALPS phenotype
Mice and humans with germline defects in components of apoptotic signaling can
develop profound alterations in normal lymphocyte homeostasis and development. These
abnormalities, collectively referred to as autoimmune lymphoproliferative syndrome
(ALPS), include the accumulation of an aberrant DN lymphocyte population, the
development of auto-antibodies, and impaired survival108,109. Given the potential safety
concerns related to disabling normal Fas signaling in mature T cells, we performed longterm immune-monitoring of animals that received FasDDD DNR-modified T cells more
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than 6 months prior (Figure 21A).
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Figure 21. Transfer of Fas DNR-modified T cells does not result in acquired ALPS.
(A) Experimental design to analyze long-term persistence of WT pmel-1 CD8a+ T cells modified with Fas∆DD or empty
vector control in B6 mice. (A) Representative FACS plots and (B) summary bar graph of the frequency of
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modified with FasDDD DNR or an empty vector control. All data shown is representative of 5 independent experiments,
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This time point was chosen as mice with germline defects in Fas typically develop overt
clinical manifestations within the first 3.5-5 months of life, depending on the background
strain110,111. Using unmanipulated B6 WT and Fas-deficient lpr (B6-lpr) mice as
respective negative and positive controls for the ALPS phenotype, we assessed the
frequency of CD3+B220+ lymphocytes in the spleens of mice who had previously
received ACT of Thy1.1+Vb13+ pmel-1 T cells modified with the FasDDD DNR or empty
vector control. As expected, the spleens of B6-lpr mice exhibited a significant
accumulation of abnormal CD3+B220+ lymphocytes relative to WT controls (Figure 21B
and C; P<0.05, P<0.001). By contrast, neither of the mice receiving T cells modified with
the empty vector control or Fas DNR exhibited a significant increase in this population.
To exclude the possibility of transformation of the modified T cell population, we
assessed the long-term persistence and phenotype of the transferred Vb13+Thy1.1+
engineered T cells. Consistent with our findings at intermediate time points, we found T
cells engineered with FasDDD DNR persisted at higher numbers than cells modified with
the empty vector after >200d (Figure 21D and E; P<0.05). Long-term persisting Fas
DNR-modified T cells maintained a conventional CD3+B220- phenotype. These data
indicated that adoptively transferred pmel-1 T cells expressing the Fas DNR did not
undergo abnormal lymphoproliferation in B6 hosts.
It was previously shown that expression of a transgenic TCR crossed to a Fasdeficient lpr background can limit the development of ALPS112. Additionally, the B6
strain manifests lymphoproliferative symptoms at a slower rate compared with other
strains110,111,113. We therefore performed additional experiments to assess the safety of the
FasDDD DNR modification by adoptively transferring an open T cell repertoire genetically
engineered with either Fas DNR or empty control into the ALPS-susceptible MRL-Mp
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strain. Fas-deficient mice on an MRL background (MRL-lpr mouse) develop
autoantibodies, nephritis, and splenomegaly more severely and many months earlier than
B6-lpr mice (Figure 22A)110,111,113.
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Figure 22. Fas DNR expression does not induce lymphoproliferation in the ALPS-susceptible MRL strain.
(A) Schematic comparing the onset of lymphoproliferation in B6-lpr mice at 6-9 months (top) to the MRL-lpr strain at
3-4 months. (B) Experimental design to analyze long-term persistence of WT anti-CD19-CAR expressing CD8a+ T cells
modified with Fas∆DD or empty vector control in WT MRL-Mp mice. A total of 3x106 of anti-CD19-CAR+ CD8a+ T cells
were infused i.v. into sublethally irradiated (6 Gy) mice. Recipient mice received IL-2 by daily i.p. injection for 3d and
the spleens were harvested for analysis after 93d.

On the MRL genetic background, Fas-deficient mice with the endogenous lpr
mutation develop lethal pathology related to autoimmune lymphoproliferative disease
within 4 months of birth. In comparison, B6-lpr mice develop splenomegaly and
lymphadenopathy after 6-8 months and autoantibodies, but not autoimmune disease. We
therefore felt the MRL-lpr model represented an ideal second model that encompassed
the high sensitivity necessary to detect ALPS disease within a practical and reasonable
time frame.
We used WT MRL-Mp mice at 8 weeks of age as recipients for syngeneic
adoptively transferred T cells modified with the FasDDD DNR (Figure 22B). This WT

56

strain does not develop ALPS or lymphoproliferation if left untouched. As a positive
control for ALPS, we used aged-matched, untouched MRL-lpr mice.
To induce activation and expansion of adoptively transferred T cells in this
ALPS-susceptible strain, we co-transduced open repertoire T cells from the MRL-Mp
mouse with an anti-CD19 CAR and the Fas DNR or control vector. As shown below in
Figure 23, T cells co-transduced with the anti-CD19 CAR and the FasDDD DNR exhibited
enhanced persistence and provided for superior B-ALL survival compared with control
modified T cells. Use of the anti-CD19 CAR in these experiments was advantageous for
several reasons. Anti-CD19 CAR modification promoted strong in vivo proliferation of T
cells transduced with Fas DNR or empty vector control through recognition of
endogenous CD19+ B cells. This ensured that a full TCR repertoire modified with the Fas
DNR was activated and expanded. Of note, recently published data indicate that T cells
modified with a CAR are still able to undergo stimulation through their TCR93,114.
As outlined above in Figure 22B, we infused FasDDD or empty transduced, antiCD19 CAR+ T cells into WT MRL-Mp mice (Fas sufficient) one day after sublethal
irradiation. Engraftment of transferred T cells was supported with daily intraperitoneal
injections of IL-2 over 3d. Mice were then sacrificed 3 months later when age-matched,
MRL-lpr control mice began to expire from lymphoproliferation and autoimmunity.
We analyzed the spleens of MRL mice that received no cells (PBS), or anti-CD19
CAR+ T cells transduced with FasDDD or empty control and compared these to the spleens
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of age-matched, Fas-deficient MRL-lpr mice (Figure 23A).
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Figure 23. Fas DNR expression does not induce lymphoproliferation in the ALPS-susceptible MRL strain.
A total of 3x106 of anti-CD19 CAR+ CD8a+ T cells were infused i.v. into sublethally irradiated (6 Gy) mice. Recipient
mice received IL-2 by daily i.p. injection for 3d and the spleens were harvested for analysis after 93d. (A) Summary
numbers of spleen weight in recipient mice, compared to age-matched wild type mice receiving PBS or Fas-deficient
MRL-lpr mice (negative and positive controls, respectively). (B, C) Representative FACS plots (B) and (C) summary bar
graph of the frequency of CD3+B220+ double negative lymphocytes in the spleens of recipient and control mice. (D)
Summary bar graphs of corrected levels of anti-nuclear antigens (top) and anti-dsDNA Ig (bottom) as measured by
ELISA. (E, F) Summary bar graphs demonstrating the persistence (E) and surface phenotype (F) of transferred Thy1.1+
T cells modified with FasDDD DNR or an empty vector control. n=7 mice per cohort. ****P<0.0001, ***P<0.001,
**P<0.01, *P<0.05, ns = not significant (one-way ANOVA, corrected with Tukey’s multiple comparisons).

We found that spleens from the age-matched MRL-lpr mice were significantly greater in
weight when compared to all other treatment groups. Importantly, we measured no
difference in spleen sizes between PBS-treated mice and mice that received anti-CD19
CAR-transduced cells modified with either the FasDDD or control. Flow cytometry
analysis of splenocytes demonstrated a robust expansion of unusual double-negative,
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CD3+B220+ lymphocytes in the spleens of MLR-lpr mice which collectively accounted
for >30% of all lymphocytes (Figure 23B and C). By contrast, the frequency of
CD3+B220+ lymphocytes in the empty or FasDDD T cell-treated mice were similar levels
to levels observed in the PBS control mice.
To assess for the development of autoimmune disease, we performed serum
analysis of all treated animals using samples from MRL-lpr mice as a positive control.
We found that mice which received anti-CD19 CAR+ T cells modified with FasDDD or
empty vector had low anti-nuclear and anti-dsDNA antibody titers comparable to the no
treatment control. In contrast, serum from the MRL-lpr positive control mice
demonstrated high titers of both auto-antibodies (Figure 23D).
In the absence of uncontrolled lymphoproliferation and the formation of autoantibodies, we found that that anti-CD19 CAR+ T cells co-transduced with Fas DNR
persisted at significantly higher levels in the spleens of recipient MRL-Mp mice
compared with control modified anti-CD19 CAR+ T cells (Figure 23E). Further, the
persistent Fas DNR-modified CAR+ T cells did not acquire a greater proportion of
aberrant CD3+B220+ cells compared with control modified CAR+ cells (Figure 23F).
These results directly mirrored our findings using Fas DNR-modified pmel-1 T cells
transferred into BL6 hosts (Figure 21D and E).
Finally, to assess whether the ALPS-susceptible MRL-Mp recipient mice
developed lung pathology following adoptive transfer of Fas DNR-modified T cells, we
performed a blinded pathologic assessment of H&E stained lung specimens. Consistent
with previous reports115, we found that the Fas-deficient MRL-lpr mice developed a
dense mononuclear cell inflammatory lung infiltrate in the perivascular and
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peribronchiolar regions (Figure 24 A and B).
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Figure 24 Adoptively transferred T cell modified with Fas DNR do not induce an inflammatory infiltrate in the lungs of
ALPS-susceptible MRL host mice.
(A) Representative H&E stained micrographs and (B) summary graph demonstrating the intensity of inflammatory
mononuclear cell infiltrates in the lungs of treated mice. The red arrow and red star point to areas of dense perivascular and peri-bronchiolar mononuclear inflammatory infiltrates, respectively. Scale bar = 300 m. All images were
scored in a blinded fashion by an interpreting pathologist. ***P<0.001, ns = not significant (one-way ANOVA,
corrected with Tukey’s multiple comparisons).

By contrast, mice treated with FasDDD- or control-modified T cells did not display
evidence of an increased inflammatory infiltrate relative to PBS-treated control injection.
Further, we observed no evidence of pulmonary fibrosis.
Taken together, these data in both the B6 and MRL-Mp strains demonstrate that
despite the augmented survival of the FasDDD DNR T cells, we measured no evidence of
uncontrolled lymphoaccumulation, formation of a Thy1.1+CD3+B220+ population, or
evidence of autoimmunity. Based on the data in Figures 21-24, we conclude that infusion
of mature T cells impaired in Fas signaling likely will not result in an acquired
lymphoproliferative phenotype in cancer patients.
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T cell-intrinsic disruption of Fas signaling enhances anti-tumor efficacy following
ACT
Having established that adoptively transferred T cells engineered with a Fas DNR
results in enhanced persistence without long-term toxicity, we next evaluated the antitumor efficacy of these cells. Pmel-1 T cells underwent stimulation and retroviral
transduction either with FasDDD or an empty vector control. This was followed by restimulation and further expansion to mimic the more differentiated T cell populations
present in the circulation of cancer patients6,84 (Figure 25A).
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Figure 25. Adoptive transfer of mutant Fas-bearing, tumor-reactive T cells improves control of tumor growth.
Pmel-1+ CD8+ T cells were grown and transduced as described in Figure 17C. A) Experimental design showing the
generation of pmel-1 T cells bearing mutant Fas constructs to determine effect of overexpression of mutated Fas
during adoptive T cell therapy. B-C) 5x105 bead-purified Thy1.1+ cells from each condition were injected into sublethally irradiated (6 Gy) C57BL/6 mice that had B16 melanoma tumors expressing human gp100 peptide
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tumor-bearing mice. Tumors were measured in blinded fashion by another investigator. B) Wilcoxon rank sum test. C)
Log-rank Mantel Cox test. *p < 0.05 **p<0.01 Data representative of two experiments, each with 5-8 mice per cohort.
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After 11d, transduced T cells from each condition were isolated to >98% purity using
anti-Thy1.1 microbeads, then separately injected into sublethally irradiated mice bearing
established B16 melanoma tumors. Treated mice also received IL-2 by i.p. injection.
Relative to untreated controls, all mice who received adoptively transferred pmel-1 T
cells experienced a significant delay in tumor growth (Figure 25B). However, those mice
that received T cells engineered with the FasDDD DNR exhibited enhanced tumor control
(Figure 25B; P<0.001) and significantly improved animal survival relative to controlmodified pmel-1 cells (Figure 25C; P<0.05 and P<0.01).
We recently discovered that Fas stimulation can induce non-apoptotic
Akt/mTOR-signaling, resulting in augmented T cell differentiation67,116,117. Consistent
with our previous results, we found that exposure to lz-FasL caused a dose-dependent
increase in phosphorylated- (p) AktS473 and pS6S235,S236 in T cells transduced with an
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empty vector control (Figure 26A and B).
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representative of 3 (A, B) and 5 (C, D) independent experiments. *P<0.05, (Wilcoxon rank sum test).

Expansion of control-modified cells resulted in an accumulation of TEM-like cells with a
reduced capacity to produce IL-2 (Figure 26C and D). By contrast, T cells transduced
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with either FasI246N or FasDDD did not increase Akt or S6 phosphorylation following lzFasL stimulation and were protected from augmented Akt-mediated T cell differentiation.
These cells retained a predominantly TCM-like phenotype and the capacity to produce IL2.
In several different animal models47,49,94 and clinical trials16,118, transfer of TCMlike cells was associated with superior tumor regression compared to transfer of TEM-like
cells. These findings raised the possibility that the superior tumor regression observed
with Fas DNR-modified cells might be attributable to differences in cell differentiation
rather than protection from Fas-mediated T cell death. To control for the variable of T
cell differentiation status, we normalized for T cell differentiation status at the time of
cell infusion by isolating to >96% purity transduced, TCM-like phenotype cells
(Thy1.1+CD44+CD62L+) by FACS sorting (Figure 27A).
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Figure 27. Adoptive transfer of Fas DNR-modified T cells enhances anti-tumor efficacy independently of T cell
differentiation status.
(A) Representative FACS plots demonstrating the purity of sorted CD62L+CD44+Thy1.1+ TCM-like pmel-1 T cells
modified with Fas DNRs or empty vector control prior to infusion. All treated mice received sublethal irradiation (6
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Gy) prior to cell infusion followed by 3d of i.p. IL-2. (B) Tumor regression and (C) survival of mice bearing 10d
established B16 melanoma tumors who were untreated or received 5x105 of sort-purified TCM-like Thy1.1+ modified
cells. All tumor measurements were performed in a blinded fashion by an independent investigator. Representative
results from two independent experiments are shown as mean ± SEM using n=5-8 mice/cohort. Statistical
comparisons performed using Wilcoxon rank sum test (B) or the Log-rank Mantel Cox test (C), *P< 0.05.

Central memory-like sorted T cells were subsequently transferred into sublethally
irradiated, B16 tumor-bearing mice as described in Figure 25. We found that even when
normalized for TCM-like differentiation status, adoptive transfer of T cells modified with
the Fas DNRs resulted in superior tumor regression and animal survival compared with
control-modified T cells (Figure 27B and C; P<0.05). Taken together, we conclude that
prevention of Fas-mediated cell death, not just Fas-mediated differentiation, in adoptively
transferred, tumor-reactive T cells engineered with a Fas DNR results in superior tumor
regression and animal survival.
Due to concerns that the above improvement in anti-tumor efficacy was an artifact
specific to B16 melanoma or a self-antigen-driven transgenic TCR, we next sought to
extend our key findings related to enhanced T cell persistence, absence of uncontrolled
lymphoproliferation, and augmented anti-tumor efficacy in a new system. We made use
of a recently reported fully syngeneic anti-CD19 CAR model for the treatment of a
murine B-cell acute lymphoblastic leukemia, E2a-PBX93, to complement our original
findings treating B16 melanoma using the TCR transgenic pmel-1 model. We specifically
chose a syngeneic model over the more commonly used xenogeneic anti-CD19 CAR
treatment models for two reasons. First, we wished to ensure that the transferred T cells
were fully responsive to host-derived FasL in addition to FasL expression by tumor cells
and the adoptively transferred T cells. Second, we wished to avoid the potentially
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confounding influence of xenogeneic reactivity on AICD induction in the transferred T
cells.
We first established that dual transduction of B6 CD8a+ T cells with retroviral
constructs containing the FasDDD or empty vector and anti-CD19 CAR was feasible
(Figure 28A and B).
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Figure 28. Expression of Fas DNR enhances anti-apoptotic functions and T cell survival in anti-CD19 CAR model.
(A) Representative flow plots and (B) summary data of double transduction of B6 CD8a+ T cells with retroviral
constructs encoding anti-CD19 CAR and Empty or Fas DNR. Analysis performed on d11 cells after Thy1.1 beadenrichment on d6. Protein L is utilized for detection of CAR expression and Thy1.1 for Fas DNR or control vector. (C)
Summary bar graph of relative T cell viability (to FasDDD) following overnight culture in cytokine-free media alone, in
the presence of lz-FasL (100 ng mL-1), the presence of 2 µg mL-1 each of anti-CD3 and anti-CD28, or leukemia cell line
E2a-PBX. Data shown after gating on Thy1.1+ lymphocytes. Data shown is representative of 3 independently
performed experiments and is displayed as mean ± SEM with n = 3 per condition. ****P<0.0001, *P<0.05 (two-way
ANOVA).

Using Protein L to identify CAR-transduced T cells, we found that co-transduction
efficiencies were similar using FasDDD and the empty vector control following Thy1.1bead enrichment.
We next sought to analyze how the anti-CD19 CAR responded to various death
inducing stimuli, including cytokine withdrawal, exposure to antigen-expressing tumor
cells (the syngeneic leukemia E2a-PBX), and exogenous FasL signaling (lz-FasL; Figure
28C). Even with a chimeric antigen receptor, through which the general understanding of
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signaling is still not fully elucidated, we found that the expression of FasDDD protected T
cells from death as induced by cytokine withdrawal or exposure to antigen on tumor cells
in comparison to empty vector transduced T cells. Interestingly, exposure to RICD
through the endogenous TCRs (via anti-CD3/CD28) was also protected, indicating that if
anti-CD19 CAR+ cells were to encounter their cognate antigen in vivo after ACT, FasDDD
cells would maintain protection from RICD. These data indicate that the Fas DNR
protects T cells expressing a TCR or CAR from a broad range of potential apoptotic
insults adoptively transferred T cell might experience, including RICD.
We next tested if co-expression of a Fas DNR in chimeric antigen receptor
expressing T cells could mediate the same higher persistence and better anti-tumor
efficacy as we demonstrated in the pmel-1 TCR transgenic/B16 melanoma model. We
infused FasDDD or empty Thy1.1+ anti-CD19 CAR+ CD8a+ T cells grown for 11d in
culture into sublethally irradiated B6 mice bearing 4d established E2a-PBX B-ALL
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(Figure 29A).
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Figure 29. Expression of Fas DNR enhances anti-apoptotic functions and in vivo persistence in anti-CD19 CAR model.
(A) Experimental schema for the generation and infusion of WT CD8a+ T cells engineered to express anti-CD19 CAR+
along with Fas∆DD DNR or an empty vector control. Transduced T cells were enriched with an anti-Thy1.1 microbead
prior to injection and a total of 5x105 T cells were infused i.v. into sublethally irradiated (6 Gy) mice bearing 4d
established E2a-PBX leukemia. Recipient mice received IL-2 by daily i.p. injection for 3d and the spleens and bone
marrow were harvested for analysis on d14. (B) Summary data of numbers of live, CD8a+Thy1.1+ lymphocytes in the
spleens and bone marrow (BM) of recipient mice. (C) Summary data of the frequency of E2a-PBX leukemia in the
bone marrow of recipient mice. Results are representative of two independent experiments, each with n=5 mice.
*P<0.05 **P<0.01 ****P<0.0001, ns = not significant (one-way ANOVA, corrected with Tukey’s multiple comparisons).
(D) Survival of mice bearing 4d established E2a-PBX leukemia who were untreated or received 3x105 (left) or 2x105
(right) of anti-CD19 CAR+ Thy1.1+ modified cells. Representative results from four independent experiments are
shown as mean ± SEM using n=5 mice/cohort. Statistical comparisons performed using the Log-rank Mantel Cox test
(C), *P< 0.05 **P<0.01.

These mice received daily IL-2 injections for 3d to support expansion of the adoptively
transferred T cells. Fourteen days following cell infusion, we analyzed the spleens and
bone marrow, two sites of disease for the E2a-PBX B-ALL, for persistence of the
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adoptively transferred cells. We measured higher levels of Thy1.1+ FasDDD cells in both
disease sites in comparison to mice that received the empty vector-transduced T cells
(Figure 29B).
To understand the effect that the higher numbers of FasDDD T cells had on tumor
burden, we analyzed the bone marrow for leukemia burden. The E2a-PBX leukemia is
known to express classic pre-B-ALL markers such as CD19, B220 and CD93119. As seen
in Figure 29C, we found that the bone marrow in untreated (PBS) and empty vector
treated mice contained roughly 70% leukemia cells 14d after T cell treatment. However,
the mice that received FasDDD cells contained less than 1% leukemia cells in the bone
marrow. This data indicated that the CAR+ T cells expressing the Fas DNR were able to
mediate superior leukemia eradication relative to empty vector-transduced T cells.
Finally, we analyzed the survival of leukemia-bearing mice after adoptive transfer
of two different doses of second generation 28z anti-CD19 CAR-transduced T cells comodified with FasDDD or empty control. In order to provide for a treatment window, we
intentionally transferred doses of CAR-modified T cells previously shown to be
subtherapeutic in this model93. At a relatively higher cell dose (3x105 CAR+ cells), we
found that adoptive transfer of either control- or FasDDD-modified CAR+ T cells resulted
in significantly improved animal survival compared with mice which did not receive
treatment (Figure 29D, left). However, whereas all mice who received the Fas DNRmodified CAR+ T cells survived, mice that received control-modified CAR+ T cells did
not survive longer than 55d. At a further de-escalated dose of CAR+ cells (2x105), Fas
DNR-modified T cells continued to provide long-term survival in 100% of treated mice
while control-modified T cells entirely lost efficacy (Figure 29D, right). Previous reports
have demonstrated that 4-1BB-containing second generation CARs express higher levels
69

of anti-apoptotic proteins compared with CARs containing a CD28 domain120. We did
not test in these experiments whether the Fas DNR could also enhance the function of a
4-1BB-containing CAR. Thus, transfer of syngeneic anti-CD19 CAR+ T cells cotransduced with the FasDDD resulted in superior T cell persistence and survival from
established B-ALL compared with control modified anti-CD19 CAR+ T cells. Taken
together, these data in the solid B16 melanoma and liquid E2a-PBX leukemia models
indicate that Fas DNR expression in adoptively transferred, CD8a+ T cells results in
superior in vivo cellular persistence and anti-tumor efficacy, protecting T cells from
FasL-mediated death regardless of whether the targeting agent is a TCR or 28z CAR.

Genetic engineering with Fas DNR protects human T cells from Fas-mediated
apoptosis
To determine the clinical feasibility of engineering human T cells with Fas DNRs,
we designed retroviral constructs encoding the human Fas sequence mutated to prevent
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FADD binding (Figure 30).

Figure 30. Genetic engineering with Fas DNR protects human T cells from FasL-induced apoptosis.
Schematic representation of physiologic Fas signaling and the design of two human Fas DNRs. Retroviral-encoded
human Fas DNRs were designed to prevent recruitment of Fas-associated protein with death domain (FADD) either by
(i) substitution of a valine for an aspartic acid residue at position 244 of the death domain (DD; hFasD244V), or (ii)
truncation of the majority of the human intracellular death domain (hFasΔDD). An empty vector was used as a negative
control. Receptors were cloned into a bicistronic vector containing a Thy1.1 reporter. EC, extracellular domain; TM,
transmembrane domain; T2A, thosea asigna virus 2A self-cleaving peptide.

This included a human Fas variant containing a point mutation substituting a valine for an
aspartate residue at position 244 (hFasD244V)121,122, and human Fas with the majority of
the intracellular death domain truncated (del aa 230-314; hFasDDD)121,122. As with murine
Fas mutations, these mutations in human Fas have demonstrated that downstream FADD
signaling is abrogated when these mutations are expressed in various cell types. CD8+ T
cells were isolated from HD PBMC and stimulated with anti-CD3/CD28 and IL-2,
followed by transduction with hFasD244V, hFasDDD, or an empty vector control containing
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a Thy1.1 reporter (Figure 31A).
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Figure 31. Genetic engineering with Fas DNR protects human T cells from FasL-induced apoptosis.
(A) Experimental timeline for the stimulation, retroviral transduction, expansion, and testing of lz-FasL mediated
apoptosis of human CD8+ T cells derived from peripheral blood mononuclear cells (PBMCs) modified with FasD244V,
Fas∆DD, or an empty vector control. (B) Representative FACS plots (0 and 100 ng mL-1 lz-FasL) and (C) summary graph
showing the frequency of apoptotic Annexin V+ T cells at rest and 6h following exposure to titrated concentrations of
lz-FasL. Results shown after gating on transduced (Thy1.1+) or untransduced (Thy1.1-) T cells. Data is displayed as
mean ± SEM with n = 3 per condition displayed and is representative of 3 independent experiments. *P<0.05, ns =
not significant (Wilcoxon rank sum test).

In the absence of additional stimulation, both untransduced Thy1.1- and transduced
Thy1.1+ T cells remained similarly viable as measured by Annexin V and PI staining
(Figure 31B). However, when these cells were cultured in the presence of increasing
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doses of lz-FasL, we found that T cells transduced with the empty vector exhibited a
significant and dose-dependent increase in the frequency of Annexin V+ apoptotic and
necrotic cells (Figure 31B and C). By contrast, T cells modified with either hFasD244V or
hFasDDD were significantly protected from lz-FasL-mediated apoptosis. This protection
was predominantly T cell-intrinsic, as non-transduced Thy1.1- cells exhibited
significantly higher frequency of Annexin V+ cells relative to Thy1.1+ T cells transduced
with hFasD244V or hFasDDD. Thus, we conclude that genetic engineering with a Fas DNR
protects primary human T cells from FasL-induced cell death, providing a new method to
protect adoptively transferred T cells within the human TME.

Discussion
In this chapter, we tested a cell-intrinsic strategy to ‘insulate’ Fas-competent
mouse and human T cells from FasL-induced apoptosis using genetic engineering with a
series of Fas DNRs. These mutated Fas receptors were disabled in their ability to bind the
intracellular adapter molecule FADD—which recruits the signaling machinery to initiate
the extrinsic apoptotic signaling cascade—through either a point mutation in the death
domain or the removal of the entire death domain. Expression of Fas DNRs in CD8a+ T
cells protected T cells from FasL-mediated apoptosis. Functionally, adoptively
transferred Fas DNR-modified T cells exhibited superior persistence in both the
periphery and tumors of tumor-bearing animals, resulting in superior tumor regression
and overall survival. Importantly, while we observed that T cells modified with Fas DNR
exhibited enhanced survival relative to control-modified T cells as late as 6 months
following transfer, we detected no evidence of uncontrolled lymphoproliferation or
autoimmunity. These findings therefore provide a novel, potentially universal gene
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engineering strategy to enhance the function of adoptively transferred T cells against a
broad range of human malignancies, including advanced solid cancers.
One concern about overexpression of the FasI246N DNR in CD8+ T cells that have
endogenous expression of WT Fas is the possibility of a reversion to the WT Fas gene
sequence in the introduced Fas DNR construct. Reversion of a mutated gene product to
its corresponding WT sequence might pose a safety hazard if the introduced transgene is
an inactivated oncogene. For example, integration into the host genome of genetic
vaccines encoding inactivated HPV E7 or KRAS might induce cellular proliferation,
transformation, and immortalization should they revert to WT. In the case of the Fas
DNRs incorporating a single point mutation, such an event is fortunately unlikely to lead
to toxicity as a WT reversion would sensitize T cells to apoptosis. Indeed, as shown in
Figure 15, we found that cells engineered with FasWT underwent significantly greater
FasL-mediated apoptosis compared with T cells modified with an empty vector control,
while FasI246N overexpression provided full protection. Re-stimulation and growth of T
cells expressing FasWT resulted in a near complete loss of FasWT overexpression, whereas
FasI246N overexpression increased during that same period (Figure 17). These results
indicated that reversion of a point mutation in overexpressed Fas never occurred.
In previously performed experiments by others, expression of mutated Fas in
transformed human and murine cell lines104,121,122 clearly demonstrated that point
mutations in Fas lead to impaired apoptotic signaling. Protection from apoptosis occurred
even when WT Fas was also co-expressed, indicating with a different point mutation that
a reversion to WT Fas does not occur122. However, it certainly is possible that T cells
modified with the FasI246N DNR construct can, under certain conditions, perform less
efficiently relative to T cells modified with the FasDDD DNR. There could be just enough
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recruitment of FADD to the FasI246N mutated death domain that, when combined with the
high levels of overexpression of FasI246N, there is a very low level of FADD aggregation
and initiation of the extrinsic apoptotic signaling cascade. Despite the almost
undetectable recruitment of FADD shown by Imtiyaz et al.105, perhaps the ~2-fold lower
levels of FasI246N expression in comparison to FasDDD (Figure 14) can lead to a small but
significant increase in apoptosis.
To investigate these possibilities, we performed additional functional and genetic
experiments to formally test for the possibility of reversion or inefficient recruitment of
FADD. As noted above in Figure 19, we have subsequently discovered that the FasI246N
DNR construct is less efficient at protecting T cells from RICD and cytokine withdrawal
relative to FasDDD DNR. Protection from apoptosis after cytokine withdrawal as provided
by the FasI246N DNR was an unexpected finding given that Fas has not been shown to
have a role in this death-inducing pathway123. It certainly could be possible that there are
low levels of FasL expression by the T cells themselves in the co-culture, although we
have not previously observed clear FasL expression at this time point67.
The above-mentioned factors might contribute to the reduced in vivo anti-tumor
efficacy observed when an unfractionated population of T cell subsets modified with
FasI246N compared with FasDDD are transferred. We and others have previously shown that
central memory T cells are relatively resistant to apoptosis compared with effector
memory T cells67,88,123. This includes resistance to apoptosis triggered by cytokine
withdrawal123. Consequently, transfer of TCM anti-tumor T cells might minimize
differences between the two Fas DNR constructs.
We previously reported that in addition to its canonical apoptosis-inducing
functions, Fas can also promote mouse and human T cell differentiation in an Akt-
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dependent manner67,116. Consistent with these findings, we discovered that T cells
transduced with Fas DNRs were protected from lz-FasL-mediated induction of pAktS473
and pS6S235,S236. Consequently, this block in Akt/mTOR signaling minimized T cell
differentiation, promoting the accumulation of TCM-like cells which retained expression
of the lymphoid homing marker CD62L and the capacity to produce IL-2. In multiple
pre-clinical models47,49,94 and in retrospective analyses of human clinical trials16,118,
infusion of TCM-like cells was associated with superior anti-tumor outcomes compared
with TEM-like cells. These findings raised the possibility that the superior treatment
outcomes we observed using Fas DNR-modified cells might have resulted from the
infusion of less differentiated T cells, rather than prevention of apoptosis.
To address this possibility, we compared the anti-tumor efficacy of
phenotypically matched, FACS-sorted, TCM-like cells modified with a Fas DNR or an
empty vector control. We found that even when normalized for surface phenotype, Fas
DNR-modified TCM exhibited superior treatment efficacy compared with controlmodified TCM. Mechanistically, we conclude that the dominant contributor of the
enhanced in vivo anti-tumor efficacy we found using Fas DNR-modified T cells was
attributable to the disruption of cell death and not the infusion of less differentiated cells.
These findings are also consistent with recent papers from Zhu et al., Horton et al., and
Lakins et al. demonstrating that FasL-induced apoptosis of tumor infiltrating
lymphocytes limits the efficacy of immune checkpoint inhibitors61,124,125.
We previously were unable to measure pmel-1 T cells actively undergoing
apoptosis in vivo despite performing analyses every 12h during the peak of the
response126. Similarly, we could not measure differences in active apoptosis in these
experiments. Nevertheless, these data indicate that T cells became activated and
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proliferate similarly in vivo. However, likely through a reduction in apoptosis, Fas DNRmodified T cells demonstrated superior overall expansion and long-term persistence.
In conclusion, we have discovered that the FasL/Fas pathway is poised to be
activated in many patients receiving adoptive immunotherapy for the treatment of solid
cancers. We have developed novel dominant negative receptors which intrinsically
abrogate the apoptosis-inducing functions of this pathway in primary mouse and human T
cells, leading to enhanced cellular persistence and augmented anti-tumor efficacy. These
data lay the groundwork for a potential universal strategy to enhance the potency of
adoptive immunotherapies against both solid and hematologic cancers.
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CHAPTER 5: DISCUSSION
Summary of experimental work
In this body of work, we have analyzed the effects of Fas signaling modulation on
memory CD8+ T cells. Our earlier work in naïve CD8+ T cells investigated the role Fas
signaling played in encouraging the differentiation and death of TN when expanded in the
presence of FasL-bearing TMem67. Applying this knowledge to the therapeutic adoptive
transfer of T cells to treat cancer, we first set out to determine if Fas and FasL
interactions could occur in the tumor microenvironment or in the cancer patient. Analysis
of publicly available datasets on gene expression in primary tumor samples of cancer
patients revealed that 73% of cancer types have higher expression of FASLG in
comparison to normal tissues from which those cancers arise. Phenotypic characterization
of patient PBMC that would likely be utilized as a starting source of T cells demonstrated
that cancer patients have fewer TN and therefore more Fas-expressing cells in their
PBMC in comparison to HD. These analyses indicated that Fas-FasL interactions could
occur during ACT, negatively affecting the therapeutic T cells. Thus, the purpose of this
work was to determine if Fas signaling, which can induce both differentiation signals and
death signals, could be blocked during ex vivo culture of T cells to enable the more
robust growth and expansion of cells limited in their differentiation, so that these T cells
maintained cytolytic and anti-tumor capabilities upon adoptive transfer into tumorbearing animals.
First, we sought to elucidate the role of Fas signaling in defined TMem subsets
including TSCM, TCM, and TEM. We found that TMem activated and cultured ex vivo with
oligomerized FasL underwent greater differentiation and apoptosis than compared to
TMem activated alone. As we and others have established, anti-tumor efficacy of T cells is
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most successful when one infuses less differentiated cells that can develop cytolytic
capabilities in vivo but haven’t yet been acquired them in vitro47,65,91. Additionally,
infusion of greater numbers of T cells can mediate a better anti-tumor response91,126.
Thus, we hypothesized Fas signaling blockade could generate greater numbers of
younger cells.
We attempted to block Fas signaling during ex vivo culture of both murine and
human CD8+ T cells in two ways. First, we tested a T cell-extrinsic blockade, utilizing a
blocking anti-FasL antibody that can bind to FasL in such a way to prevent binding with
and aggregation of Fas. CD8+ TMem from pmel-1 TCR transgenic mice activated and
incubated in the presence of anti-FasL expanded to higher levels in vivo, acquired a less
exhausted phenotype, and more effectively treated established B16 melanoma tumors
compared to IgG controls. Similarly, open repertoire TMem expanded with anti-FasL and
genetically engineered with an anti-CD19 CAR exhibited enhanced CAR expression,
reduced differentiation, and augmented anti-lymphoma and anti-leukemia activity
compared to IgG controls.
Our studies in cell-extrinsic Fas signaling blockade during human CD8+ T cell
cultures, using a human-specific anti-FasL antibody, demonstrated that human T cells are
susceptible to lz-FasL-mediated apoptosis. However, anti-FasL blocking antibody does
not have an effect on CD8+ T cells differentiation or cell expansion. These studies with
anti-FasL in both murine and human T cells demonstrate that Fas signaling blockade acts
in a different manner than in murine T cells, which has implications for the design and
execution of T-cell-based immunotherapies in patients with cancer or infectious disease.
One of the few correlates with response to ACT, for T cells engineered to express
anti-CD19 CAR or through TIL, is the presence and persistence of less differentiated T
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cells62,127. Because there is interest in preventing unnecessary T cell differentiation during
ex vivo cultures, we sought to find a way to bring Fas signaling blockade into the patient
in a way that would prevent T cell death and differentiation but maintain the ability of T
cells to utilize FasL to induce cytolysis in tumor cells. Thus, we turned to overexpression
of mutated Fas through genetic engineering of T cells.
Others have tested in clinical trials whether the co-administration of an immunecheckpoint inhibitor76,77 can improve the persistence of adoptively transferred T cells.
However, these agents may not always efficiently enter the solid tumor
microenvironment128 and can cause non-specific immune activation resulting in systemic
toxicities that do not contribute to efficacy129. A cell-intrinsic strategy to enhance T cell
function exclusively within adoptively transferred T cells could contain the risk of
systemic toxicities while taking full advantage of the ability to reliably genetically
engineer human T cells for clinical applications.
Herein, we found that construction and expression of retroviral constructs
engineered with mutated Fas was a feasible means to disable Fas signaling in a cellintrinsic manner in CD8+ T cells. These Fas DNRs functioned in both primary mouse and
human T cells to prevent FasL-induced apoptosis. In murine CD8+ T cells, Fas DNR
overexpression enabled adoptively transferred T cells persist at higher levels in vivo after
homeostatic expansion and in response to antigen-bearing tumor burden. Additionally,
Fas DNR expression on T cells enabled better control of tumor growth and prompted
longer animal survival in two different murine tumor models. Most crucially, we
demonstrated that cell-intrinsic Fas signaling blockade works even if differentiation
differences between Fas DNR-expressing and empty vector-transduced T cells are
accounted for, giving hope that protection from Fas-mediated apoptosis will be an
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important factor in human cancer patients. Finally, long-term testing in two mouse strains
revealed no uncontrolled lymphoproliferation by adoptively transferred Fas DNRexpressing T cells, implying that mature T cells can lose Fas function and not induce
lymphoproliferation or autoimmunity. Collectively, these results provide a potentially
universal strategy to enhance the durability and survivability of adoptively transferred T
cells in a wide range of human malignancies following ACT.

Why is cell-intrinsic Fas signaling blockade superior to a cell-extrinsic blockade?
We and others have shown that Fas signaling can result in both death and T cell
differentiation67,70,116. A simple approach to incorporate Fas signaling blockade to
improve ACT is through the use of anti-FasL blocking antibody. This reagent could
easily be added to current culturing methods and could quickly be manufactured for a
clinical-grade product. However, it is very important to determine if blockade of a FasFasL interactions in vitro confers benefit towards adoptively transferred T cells in vivo.
We previously reported that expansion of an unfractionated population of pmel-1
T cells in vitro with anti-FasL antibody blockade preserved a population of less
differentiated central memory T cells relative to IgG1 control antibody-treated cells67.
Transfer of an unfractionated population of T cells expanded in the presence of an antiFasL antibody resulted in superior B16 tumor regression compared with IgG1-treated
control T cells. However, the anti-FasL treated T cells were less differentiated at the time
of cell infusion than the IgG1-treated cells in these experiments. We and others have
previously shown that less differentiated T cells confers superior anti-tumor efficacy
compared with more mature T cells47,91,94.
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We therefore sought to test if in vitro FasL blockade benefits the in vivo antitumor efficacy of adoptively transferred T cells when differentiation status is normalized.
We FACS-sorted TCM-like CD62L+ cells following in vitro expansion in the presence of
anti-FasL or IgG1 control. As shown in Figure 11E, we discovered that the in vivo
benefit following anti-FasL blockade is lost when cells are normalized for a TCM
phenotype. These data suggest that the anti-tumor benefit of cell-extrinsic, antibodybased blockade of FasL-Fas interactions in vitro was attributable to restraining T cell
differentiation prior to adoptive transfer. T cells lose the protection provided by the
blocking anti-FasL antibody upon transfer into the TME, allowing for FasL-mediated
apoptosis to occur (Figure 32, left).
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Figure 32 Proposed mechanisms demonstrating protection provided by cell-intrinsic and cell-extrinsic Fas blockade.
Provision of a blocking anti-FasL antibody during the ex vivo activation and growth of T cells provides a cell-extrinsic
means of Fas-FasL interactions (left). This can lead to greater expansion of T cells that are also less differentiated in
comparison to cells activated in the presence of a control antibody. However, adoptive transfer of the T cells into the
patient allows for FasL to interact with the unprotected Fas on the surface of T cells, leading to Fas-mediated
apoptosis in the tumor microenvironment (TME). Genetic engineering of T cells to express a mutated Fas dominant
negative receptor (Fas DNR) allows for the blockade of Fas signaling in T cells during ex vivo T cell culture (right). As

82

this Fas signaling disruption is cell-intrinsic, T cells are equipped to disrupt Fas signaling as they are transferred into
the patient, allowing for protection from FasL-mediated apoptosis at all times in vivo.

By contrast, as shown in Figure 27B and C in Chapter 4, T cells modified with the
FasDDD DNR confer superior in vivo anti-tumor responses even after normalization for a
TCM phenotype at the time of transfer. When taken together, the data in Figures 11E and
27B and C suggest that the benefit of the Fas DNR occurs through its influence on T cell
behavior in vivo, rather than in vitro. These data imply that protection from Fas-mediated
apoptosis is crucial in vivo as a T cell encounters antigen, migrates to the tumor site and
attempts to lyse antigen-bearing cells (Figure 32, right). Expression of the Fas DNR in
human CD8+ T cells might not provide protection from differentiation but will still
protect against FasL-mediated apoptosis regardless of the source of FasL in the TME.
Our data has important implications for the clinical application of Fas-FasL
blockade. Others have indicated that systemic application of Fas-Fc or anti-FasL as an
anti-cancer treatment could be beneficial61,125,130 but use of these reagents alongside ACT
would block the ability of T cells to utilize FasL to induce cytolysis of tumor cells. There
is evidence in murine models that Fas stimulation could possibly induce some histologies
to differentiate or migrate74, and we wish to avoid any systemic perturbations that might
inadvertently benefit the tumor or TME. With the Fas DNR, the T cell brings the
protection from FasL with it into the patient.
Our data indicates that Fas-mediated differentiation does not appear to be a factor
during ex vivo human T cell culture, and protection via ex vivo application of anti-FasL
provides no benefit for clinical use. However, we and others have firmly established that
FasL can mediate apoptosis and drive differentiation in vivo, and this may be important
during treatment of human cancer. While we have clearly demonstrated that cell-extrinsic
blockade can prevent death and differentiation in murine CD8+ T cells during ex vivo
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culture, these same processes must occur in vivo as a T cell migrates to secondary
lymphoid organs, encounters antigen-bearing cells, and attempts to lyse those cells. As T
cell persistence is correlated with cancer regressions in patients receiving ACT, we hope
that protection from Fas-mediated death would provide a persistence benefit in humans as
well. Because any Fas signaling is prevented by expression of the Fas DNR expression in
vivo, this cell-intrinsic method is why cells with the same differentiation state mediate
better anti-tumor efficacy only when the Fas DNR is expressed and not when anti-FasL
treated cells are used as ACT. In humans, the Fas DNR represents a tactic for a T cell to
bring permanent FasL defense into the patient, allowing for the fullest cytolytic
capabilities of those cells to attack cancer.

Considerations on the loss of Fas-mediated differentiation in human T cells
Our data revealed that the protection afforded by anti-FasL antibody against Fasmediated differentiation observed in murine T cell cultures did not translate to human T
cell cultures. Our work has not elucidated why a differentiation effect was not observed,
given that human T cells differentiate robustly when exogenous FasL is added to the
culture conditions67. Given that our goals were to increase expansion and persistence to
improve ACT, this prompted further work to ensure that at least a protection from
apoptosis was carried by T cells into the cancer patient. Thus, we made use of mutated
Fas overexpression, hoping that a permanently applied Fas blockade could mediate
effects in vivo, perhaps even with human T cells.
We did not attempt a xenograft model in which to test human Fas DNRs. A
concern when drawing conclusions about the clinical implications of this work is that we
have not tested the functional capabilities of Fas DNR-modified human CD8+ T cells in
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vivo. Confirmation of the anti-tumor benefits of the Fas DNR T cell modification in
human CD8+ T cells in a pre-clinical, xenogeneic murine model system does seem an
essential step toward the development of the Fas DNR for therapeutic use in humans.
However, the transfer of human T cells into immune-deficient mice has several
key limitations which would preclude testing our central hypothesis. For example, murine
C57BL/6 FasL does not cross react efficiently with human Fas90. Thus, transfer of human
T cells into tumor-bearing, immune-deficient mice would not test the influence FasL
expressed by all host cells on the transferred T cells. Second, the endogenous TCR on the
transferred human T cells can react to the murine antigens, triggering a potent xenogeneic
response and potentially impacting animal survival before the Fas DNR effects could be
measured. Such a potent xenogeneic TCR-induced response would likely trigger
activation induced T cell death at a far greater rate than in a syngeneic system, also
limiting proper experimental interpretation.
For these reasons, we opted to confirm our key findings with the Fas DNR related
to enhanced T cell persistence, absence of uncontrolled lymphoproliferation, and
augmented anti-tumor efficacy in a wholly syngeneic system. We made use of a recently
reported fully syngeneic anti-CD19 CAR model for the treatment of a murine B-cell
acute lymphoblastic leukemia93,119 to complement our original findings treating B16
melanoma using the TCR transgenic pmel-1 model.
While it is technically feasible to transfer human T cells into an immune-deficient
mouse to treat a human xenograft tumor, the deficiency of host FasL signaling strength
would undermine any positive results and confound conclusions and hypotheses that
could be drawn from those results. Again, results might also depend on the cancer
histology we choose to test. Given the long-term safety of the Fas DNR-engineered cells,
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the observed decline in frequency of transferred T cells we observed over time, and with
the inclusion of a suicide mechanism, we feel it is safe to test the Fas DNR directly in a
Phase I clinical trial, likely in a trial that will already be transducing cells to impart
antigen specificity.

Addressing ALPS concerns after ACT of Fas DNR-expressing T cells
One concern regarding our use of pmel-1 transgenic T cells in the B6 mouse
strain to analyze ALPS development relates to previous work demonstrating that
expression of a transgenic TCR in the lpr mouse strain can abrogate lymphoproliferation.
The authors compared lymphocyte composition in lpr mice containing open repertoire T
cells to lymphocytes in lpr mice in which a transgenic TCR specific for the H-Y male
antigen was expressed112. The authors found that both male and female lpr/lpr mice with
open repertoire T cells develop lymphadenopathy. However, neither male nor female
lpr/lpr mice that also express a transgenic TCR develop lymphadenopathy. Further
characterization of the lymphocytes in the mice demonstrate that CD3+B220+
lymphocytes—those unusual lymphocytes that prompt the splenomegaly and
lymphadenopathy characteristic of ALPS—develop only in the open repertoire lpr/lpr
mice, and not in the lpr/lpr expressing a transgenic TCR. It is certainly possible that
pmel-1 TCR transgenic T cells adoptively transferred into mice may not be capable of
inducing ALPS. This is reassuring from a clinical perspective, as we do not want to
induce lymphoproliferation with adoptive transfer of Fas DNR T cells, but merely want
to protect T cells from FasL-induced apoptosis and differentiation.
Thus, we found it absolutely necessary to analyze the effects of adoptive transfer
of open repertoire T cells transduced to express both anti-CD19 CAR and the Fas DNR,
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in the MLR-Mp strain (Figures 22-24) that were described in detail above. We found the
results to be sufficient in detailing that multiple T cell types can be safely adoptively
transferred without conferring lymphoproliferation over several months.
In our experiments above, we transferred T cells of a single specificity (gp100)
which potentially limited the development of autoimmune pathology in organs such as
the kidney or lung. Of note, recent published data indicates that T cells modified with a
CAR are still able to undergo stimulation through their native TCR114. We share others’
concerns regarding the potential of Fas DNR overexpressing T cells to cause pathology
when used in a therapeutic setting. Fas DNR now joins a list of other candidate DNRs
with which a T cell might be modified to intrinsically disrupt signaling by immunesuppressive factors present within the tumor microenvironment, including transforming
growth factor beta (TGFb)131 and the ligands for programmed cell death protein 1 (PDL1/L2)132. Disruption of Fas using a short hairpin RNA approach has been reported in
human T cells in vitro133; however, due to the relatively poor efficiency of Fas
knockdown, this approach required lengthy in vitro selection. Furthermore, the in vivo
anti-tumor capacity of these cells was not tested.
Although Fas is a critical mediator for initiating the extrinsic apoptotic signaling
cascade, intrinsic apoptotic pathways remain intact in our cells. Thus, competition for
homeostatic cytokines, neglect due to an absence of antigen or IL-2, and T cell
exhaustion may all contribute to regulating the homeostasis of the Fas DNR cells in vivo.
Despite these reassuring safety data in mice, refinement of this approach for clinical
application will include the introduction of a suicide mechanism, such as expression of a
truncated EGFR upstream of the Fas DNR134,135 or an inducible caspase 9 variant.
Expression of either of these molecules in our Fas DNR-expressing T cells allows
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clinicians to administer a well-tolerized drug to induce selective death in the adoptively
transferred T cells should any T cell-related toxicity occur. Inclusion of a suicide
mechanism will ensure that if a heretofore unobserved problem should arise with Fas
DNR in human patients, then eradication of the problematic T cells will be easy to
accomplish.

Considering the source of FasL during ACT
Our analyses indicated that FASLG expression is enriched within the
microenvironments of many human tumors. However, analysis of tumor-containing
samples from the TCGA dataset does not define which specific cell type is expressing the
ligand. Using immunohistochemical protein staining, previous studies have identified that
FasL can be expressed directly on the surface of many of the solid cancers identified in
our pan-cancer analysis. This includes cancers of the breast, colon, brain, kidney, and
cervix74,136. Additionally, recent studies have identified that FasL is expressed along the
luminal surface of the neovasculature surrounding human ovarian and brain cancers,
creating a tumor endothelial death barrier limiting T cell infiltration74,130.
It is also possible that FasL can be expressed within the TME by cells of both the
innate and adaptive immune system. This possibility has previously been shown by
others61 and is further suggested by our own analysis demonstrating a high degree of
correlation between FASLG and many immune-related genes. Additionally, we find that
Fasl is upregulated on murine TMem after activation, indicating it is possible for T cells to
contain both Fas and FasL and for those molecules to interact to induce selfapoptosis67,137. Collectively, these data suggest that the source of FasL is likely to be
tumor histology dependent, giving rise to situations where many cell types can express
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FasL in one type of cancer and restriction of expression to just one cell type in a different
cancer. Thus, a T cell-intrinsic Fas DNR approach which does not compromise the FasLmediated tumor-killing capacity of the transferred T cells is likely to have broad
applicability across a range of cancer types.
Our analysis demonstrating higher FASLG expression in TMEs could lead to the
hypothesis that FasL expression can contribute to the pathogenesis of human cancers and
therefore influence patient survival. We found the majority of primary untreated tumors
(27 of 34 histologies) in the TCGA dataset showed no significant correlation between
high and low FASLG expression and overall survival. The remaining 7 tumor histologies
demonstrated a mix of high and low FASLG expression associating with worse overall
survival. These data suggest that for the majority of cancer types represented in the
TCGA database, FASLG expression does not consistently influence either pathogenesis
or the natural history of the disease. However, this data was generated from untreated
tumor samples from patients who underwent a wide and unknown variety of anti-cancer
treatments. Extrapolating too much information from these samples could be misleading,
and we cannot presume much in terms of a predictive response to ACT.
These analyses highlight the unique usefulness of the Fas DNR in comparison to
other types of Fas signaling blockade, especially those treatments that are administered
systemically. FasL expression could change in both the tumor microenvironment and in
the host as the cancer patient is prepared to receive adoptively transferred T cells. A
crucial step to ensuring expansion of the T cells in vivo requires pre-treating patients with
a lymphodepleting regimen, either through chemotherapy or irradiation, or both10,29.
Previous works has demonstrated that host irradiation can lead to higher expression of
FasL before immune reconstitution138, and others have shown that FasL is highly
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upregulated on non-lymphoid cells in response to lymphodepletion and strong immune
stimulation139. In our own experiments, we demonstrated that the Fas DNR can protect T
cells from undergoing apoptosis in response apoptotic stimuli besides exogenous FasL.
This includes activation induced cell death and cytokine withdrawal. In two recent
reports from Lakins et al. and Horton et al., RICD has been shown to be a critical barrier
to effective cell-based immunotherapies124,125. These additional mechanisms of action for
the Fas DNR need not depend on the presence of FasL within the tumor
microenvironment. Regardless of the cellular source of FasL, or the many forms
apoptosis induction can take, Fas DNR-engineered T cells will withstand these
onslaughts better than extrinsically blocked adoptively transferred T cells.

Combining the Fas DNR with other external modulators of T cell function: Akti,
elevated [K+]
Our data suggests that Fas-mediated differentiation in human T cells occurs on a
timescale eclipsing the ex vivo culture period of most protocols. Given the pre-clinical
data others have generated showing better anti-tumor efficacy with less differentiated
human T cells94, it still remains our goal to control T cell differentiation in vitro. Our
investigations into non-apoptotic signaling through Fas implicated the kinase Akt as a
potential mediator. Akt activation through the TCR or IL-2 signaling can drive CD8+ T
cell differentiation towards acquiring effector function, and we hypothesize that Fas
signaling can have an additive effect on Akt signaling strength activated through other
receptors. We and others have extensively studied inhibition of Akt during in vitro
culture of murine and human T cells, finding that addition of a specific Akt inhibitor to T
cell cultures can withhold differentiation and acquisition of effector function in vitro, yet
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upon transfer in vivo mediate better control of tumor growth140-142. While it is not always
the case with human T cells that Akt inhibition can lead to greater numbers of T cells ex
vivo, Akt inhibition is not so strong as to be detrimental for T cell expansion. Combining
Akt inhibition with the genetic engineering of T cells with the Fas DNR might be
beneficial for leading to more CD62L+ T cells, and potentially a more efficacious ACT
product.
Another means of limiting T cell differentiation in vitro could be through the
application of elevated potassium concentration ([K+]) during ex vivo cell culturing.
Work in the Restifo Laboratory examining the lack of functionality by TIL in the tumor
microenvironment found that extracellular [K+] in the TME could elevate intracellular
[K+] in the T cell and prevent the acquisition of many T cell cytolytic and effector
functions143. Addition of isotonic [K+] to the cell culture medium led to less differentiated
cells, and this too was mediated through the Akt signaling pathway. Combination of Fas
DNR expression during activation and culturing in elevated [K+] media could combine to
increase T cell expansion while simultaneously limiting in vitro differentiation. Future
studies to determine the effects of either of the above-mentioned combinations could
elucidate if simultaneous brakes on the Akt signaling pathway could generate a better
ACT product.

Combining the Fas DNR with current clinical trial approaches: neoantigen-specific
TCRs and iPSC
Many solid tumors fail to express high levels of shared antigens, such as cancer
testis, differentiation or overexpression antigens44,56, which limits the current
applicability of “off-the-shelf living drugs” that are touted as cancer treatments in the
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near future. However, each patient’s cancer is driven by mutations that arise during the
progression of a normal cell towards one that becomes cancerous144,145. Mutations are
generally stochastic and occur throughout the genome, including within the ~20,000
protein-encoding genes. Certain mutations – in particular gain-of-function mutations in
proto-oncogenes and loss-of-function mutations in tumor suppressor genes – contribute to
cancer formation by stimulating disinhibition of cell growth, division and survival.
However, many or most mutations are thought to be ‘passenger’ mutations, without clear
functions in the transformation of the cell from normal to tumor.
Non-synonymous mutations induce amino acid codon switches in protein
sequences that can result in new epitopes that can be displayed by HLA molecules and
recognized by a patient’s T cell as altered self. While an off-the-shelf reagent seems
likely to be most useful to patients, the hard work in generating GMP-grade cell
manufacturing protocols and facilities has already been done for CD19-CARs and could
be easily adapted to targeting a patient’s unique mutated antigens instead.
T cells capable of recognizing patient-specific, mutated antigens expressed by
tumors can be found in the majority of excised tumor lesions146,147. Every cancer has a
unique set of tumor-specific mutations148-151. Mutated ‘self’ antigens are likely to be
present in cancer cells, at rates potentially far higher than shared or overexpressed
antigens and could form neoantigens recognized by a patient’s TIL.
It is important here to distinguish cancer neo-epitopes from neoantigens. The
former term indicates amino acid sequences that are presented by MHC on a cell surface,
and the latter term is reserved for epitopes presented by a cell that contains sufficient
MHC-peptide expression and can actually induce T cell responses from the available
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TCRs in the patient. Thus, TIL from individual patients may contain TCRs that could
recognize mutation-containing epitopes.
Neoantigen-reactive TCRs can be harnessed to target only the cancer, thus
avoiding targeting the healthy tissues of the host/patient. Since the most recent FDA
approvals of adoptive T cell therapies have developed several GMP-grade manufacturing
facilities, it now stands that these same capabilities can be utilized to search for and grow
out cancer neoepitope-specific T cells, or isolate those TCRs, so that ACT can take the
next step towards personalized immunotherapy.
A new effort in the Surgery Branch at the NCI aims to tackle the problems that
arise due to the late effector differentiation stage of many TIL. Given the demands to
grow TIL to the hundreds of billions of cells, it is likely that many neoepitope-reactive
TIL are unable to undergo so much expansion in high-dose IL-2 cultures. To circumvent
the need to both test for neoepitope reactivity and grow out TIL, efforts are underway to
quickly isolate the neoepitope-specific TCRs. The TCR sequence can be obtained by
single-cell TCR sequencing after sorting for 4-1BB or OX40 upregulation152, or even
through bulk TCR sequencing of highly enriched T cell cultures. These TCRs can be
inserted into viral constructs and quickly manufactured in small aliquots just for the
transduction of a patient’s T cells. The source of a patient’s T cells will be obtained from
their peripheral blood, which likely contains many more naive and central memory T
cells than TIL. Administration of these less differentiated cells in mice has shown greater
efficacy in controlling tumor growth47,49,153 and it is presumed that TCR-transduced T
cells that have been minimally cultured will contain greater potential than exhausted,
senescent TIL.
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The new protocol utilizing individualized TCRs (NCI Trial NCT03412877) will
allow for up to 5 neoepitope-reactive TCRs to be transduced into stimulated patient
PBMC. While this number of TCRs are not often found in many patients, as mutation
screening and testing procedures improve it is possible that more reactivities will be
uncovered. Many of the patients who will likely be treated first are those that have failed
treatment with neoantigen-reactive TIL, and it will be exciting to see if less differentiated
T cells will be more efficacious during ACT. Targeting tumors with as many TCRs as the
FDA allows, covering a range of mutations, could potentially apply enough pressure to
cause a tumor to fully regress before the tumor could mutate to avoid T cell recognition.
Efforts are also underway to more thoroughly test for hotspot mutation reactivity in every
patient that expresses known driver mutations in oncogenes and tumor suppressor
genes154.
Another effort in the Surgery Branch to enhance T cell function employs induced
pluripotent stem cells (iPSC)155,156. Here we transiently express Yamanaka factors to
induce neoantigen-reactive TIL to de-differentiate into iPSC. After iPSC colonies are
established and vetted, we then re-differentiate the iPSC to hemopoietic progenitor cells,
then on through the T lymphocyte maturation stages until we obtain thymic-like
emigrants we term induced thymic emigrants, or “iTE”. By recreating a thymus
environment in vitro, we are able to generate lymphocytes that retain the ability to
express T cell co-receptors in heterodimeric form, thus avoiding the acquisition of MHCindependent, NK-like cytolytic activity and the potential for off-target killing157. This
complex and laborious process involves many different culturing conditions and
environments and is thus a longer-term effort. The exciting prospect of this project is that
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iPSCs contain the capacity to proliferate indefinitely, giving us the opportunity to grow as
many tumor-reactive, truly naive T cells that contain the TCR in its endogenous state.
Because both the iTCR trial and conversion of TIL to iPSC involve long-term ex
vivo manipulation of T cells, it will be of great interest to determine what effect
overexpression of the Fas DNR could have during these processes. Certainly, dual
transduction of the Fas DNR with a neoantigen reactive TCR is feasible and transduction
efficiencies could be improved through magnetic bead enrichment of the introduced TCR
or Fas.
Fas disruption during iPSC reversion and subsequent re-differentiation would
likely require a more thorough investigation. While genetic loss of Fas during normal
development of T cells in a thymus potentially leads to abnormal lymphocyte
selection158, it is not clear if these same problems would appear if the TCR is already
rearranged or if lymphocyte development occurs entirely in a culture dish. It is possible
that if Fas signaling is important during T cell development, then Fas disruption could
improve upon the low iPSC conversion rate efficiencies.

Concluding Remarks
The state of T cell-based immunotherapy is at an exciting crossroads. ACT for B
cell malignancies has recently entered the mainstream therapy, but the cancer regressions
and response rates seen with the anti-CD19 CAR have not transferred to other cancer
types. There is much work to be done to understand what makes ACT in other
malignancies less efficacious. We were not able to discuss here the many non-T cell
factors that could play also a role in determining the success of ACT, including
immunosuppressive cells in the TME, which antigens to target, or other pre-infusion
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therapies to that could prepare the patient to receive ACT. Regardless, it still stands that
T cells are the easiest to manipulate in a manner to improve their function specifically
while leaving all other mechanisms intact. The data presented in this thesis indicate that
Fas signaling disruption in a T cell-intrinsic manner could prove beneficial towards
improving ACT for cancer. Overexpression of a Fas DNR, easily incorporated into
standardized ex vivo culturing protocols, allows for T cells to be permanently shielded
from every encounter with FasL throughout the life of the T cell after adoptive transfer.
Combining deep sequencing technology for neoantigen discovery with multiple methods
to limit T cell differentiation, the Fas DNR can be easily combined to these technologies
to improve and highly personalize the next generation of anti-cancer treatments.
Together, these advances made towards improving T cell persistence might translate to
improving adoptive T cell therapy responses in both solid and hematologic malignancies.
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CHAPTER 5: MATERIALS AND METHODS
Human Specimens
Peripheral blood mononuclear cells (PBMC) were obtained from age- and sex-matched
healthy donors, or melanoma patients and diffuse large B cell lymphoma (DLBCL)
patients enrolled on an adoptive immunotherapy clinical protocol. All anonymous NIH
Blood Bank donors and cancer patients providing PBMC samples were enrolled in
clinical trials approved by the NIH Clinical Center and NCI institutional review boards.
Each patient signed an informed consent form and received a patient information form
prior to participation.

The Cancer Genome Atlas (TCGA) pan-cancer bioinformatics analysis
RNA-sequencing (RNA-seq) data from 34 human cancers from the TCGA dataset and 26
matched normal tissues from the GTEx dataset were collected and analyzed by UCSC
Xena in the form of normalized RNA-seq by Expectation-Maximization (RSEM) values.
FASLG gene expression as normalized RSEM counts was analyzed in each. Statistics for
Figure 2A were corrected by Mann-Whitney t test. To identify genes positively correlated
to FASLG expression, we ran a pre-ranked gene set enrichment against all KEGG
pathways in the mSigDB database. Pearson’s correlation was performed on the top 1000
genes positively correlated to FASLG expression averaged across 26 TCGA histologies.

Mice
Adult 6-12-week-old male or female C57BL/6 NCR (B6; Ly5.2+) and C3H/HeNCrl
(C3H; Ly5.2+) mice were purchased from Charles River Laboratories at NCI Frederick.
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B6.SJL-Ptprca Pepcb/BoyJ (Ly5.1+), B6.129S7-Rag1Lm/Mom/J (Rag), B6.MRL-Faslpr/J
(lpr), B6.Cg-Thy1a/Cy Tg(TcraTcrb)8Rest/J (pmel-1159), MRL/MpJ (MRL-Mp), and
MRL/MpJ-Faslpr/J (MRL-lpr) mice were purchased from Jackson Laboratory. Where
indicated, pmel-1 mice were crossed to Ly5.1, Rag, or Rag x lpr backgrounds. All mice
were maintained under specific pathogen-free conditions. Animal experiments were
approved by the Institutional Animal Care and Use Committees of the NCI and
performed in accordance with NIH guidelines.

Retroviral vectors and transduction of murine and human CD8+ T cells
Murine and human Fas cDNA sequences were synthesized and separately cloned
(Genscript) into the MSGV retroviral plasmid preceding a T2A ‘self-cleavage’ sequence
and selectable marker Thy1.1. Murine T cell transductions were performed as previously
described160. Briefly, Platinum-E ecotropic packaging cells (Cell BioLabs) were plated on
BioCoat 10 cm dishes (Corning) overnight before transfection. The following day, 24 µg
of retroviral plasmid DNA encoding MSGV-Thy1.1 (Empty), MSGV-WT-mFas-Thy1.1
(mWT), MSGV-I246N-mFas-Thy1.1 (FasI246N), MSGV-DDD-mFas-Thy1.1 (FasDDD), or
MSGV-1D3-28Z (anti-CD19 CAR92) were separately mixed with 6 µg of pCL-Eco
plasmid DNA along with 60 µL of Lipofectamine 2000 (ThermoFisher) in OptiMEM,
then applied to the Platinum-E cells for 7h in antibiotic-free 10% medium. Medium was
replaced after 7h; viral supernatant was collected from the cells after 48h and centrifuged
to remove debris. Retroviral supernatants were spun for 2h at 2000xg 32oC on non-tissue
culture-treated 24-well plates that had been coated overnight in 20 µg/mL Retronectin
(Takara Bio). CD8a+ T cells activated for 24h were added to plates that had all but 100
µL of viral supernatant removed, spun for 5m at 1500 rpm at 32oC, then incubated
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overnight. The transduction was repeated a second time the next day in the manner
described above. For human T cell transduction, 293T cells55 and RD114 were used in
place of Platinum-E cells and pCL-Eco, and transfection and virus harvest proceeded as
during the murine virus production described above.

T cell culture and Fas death assay
Human PBMC from healthy donors or patients were obtained either by leukapheresis or
venipuncture and centrifuged over Ficoll-Hypaque (Lonza) gradient to remove red blood
cells and isolate lymphocytes. Cells were washed twice with PBS containing 1 mM
EDTA, stained with fixable cell viability dye (Thermo Fisher) in PBS, then washed twice
with PBS supplemented with 2% FBS and 1 mM EDTA (FACS buffer). Untouched
human CD8+ T cells were isolated using a human CD8 isolation kit (Stem Cell
Technologies). Murine and human T cells, and E2a-PBX leukemia cells93 were
maintained in RPMI 1640 (Gibco) with 10% heat-inactivated fetal bovine serum (FBS),
1% penicillin/streptomycin (100 U/mL and 100 µg/mL, respectively; Gibco), gentamicin
(10 µg/mL), MEM non-essential amino acids (Gibco), sodium pyruvate (1 nM, Gibco),
GlutaMAX (2 mM, Gibco), 2-mercaptoethanol (0.011 mM, Gibco) and amphotericin B
(250 ng/mL, Gibco). B16-mhgp100 tumor cells (a kind gift from K. Hanada, Surgery
Branch, NCI) were maintained in DMEM (Gibco) supplemented with 10% FBS and the
above-mentioned additives.
Untouched murine CD8a+ T cells were isolated from splenocytes using a MACS CD8+
negative selection kit (Miltenyi Biotec) and stimulated in tissue-culture treated 24-well
plates with plate-bound anti-CD3 (2 µg/mL, clone 145-2C11, BD Biosciences), soluble
anti-CD28 (1 µg/mL, clone 37-51, BD Biosciences) and IL-2 (5 ng/mL). Pmel-1 T cells
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were stimulated in whole splenocyte cultures with 1 µg/mL human gp100(25-33) peptide
and IL-2 (5 ng/mL, Prometheus). Addition of 10 µg/mL of anti-FasL blocking antibody
(MFL3 or MFL4, BioLegend) or control IgG1 antibody (HTK888, BioLegend) occurred
at the start of culture and was refreshed as cultures were split. Human PBMC or CD8a+ T
cells were stimulated with plate-bound anti-CD3 (1 µg/mL, clone OKT3, BD
Biosciences), soluble anti-CD28 (1 µg/mL, clone CD28.2, BD Biosciences) for 2d, then
given IL-2 (20 ng/mL) during the remainder of culture. Addition of 10 µg/mL of antiFasL blocking antibody (NOK-1, BioLegend) or control IgG1 antibody (Mouse IgG1,k,
BioLegend) occurred at the start of culture and was refreshed as cultures were split.
Murine and human cells were stimulated for 24h before transduction with viral
supernatant on days 1 and 2 of culture. On day 3 cells were removed from Retronectincoated plates and returned to tissue-culture treated 24-well plates or flasks. Where noted
cells were grown either with vehicle or the indicated concentrations of lz-FasL, a
recombinant form of oligomerized FasL88,116. Five to six days after stimulation, T cells
were washed 2X in PBS and plated at 1-2x105 cells/well in a 96-well plate with the
indicated concentrations of lz-FasL and incubated at 37oC with 5% CO2 for 6h or 24h.
Cells were then washed twice and stained with either Annexin V and PI or Live/Dead
Fixable Dye (Thermo Fisher) as well as CD8a (clone 53-6.7, BD Biosciences) and
Thy1.1 (clone HIS51, eBioscience).

Flow cytometry, intracellular cytokine staining and phosphoflow
Cells were stained with fixable cell viability dye (Thermo Fisher) in PBS, then washed
twice with FACS buffer. Human cells were stained with the following fluorochrome-
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conjugated antibodies: CD3 (UCHT1), CCR7 (3D12), CD45RA (HI100), CD45RO
(UCHL1), CD28 (CD28.2), CD95 (DX2) (BD Biosciences); and CD27 (M-T271),
CD62L (DREG-56), CD8a (SK1), CD4 (OKT4) (BioLegend). Murine T cells, bone
marrow and splenocytes were first stained with fixable live/dead dye followed by the
following antibodies: CD3 (145-2C11), CD8a (53-6.7), Vb13 (MR12-3), Ly5.1 (A20),
Ly5.2 (104), CD62L (MEL-14), CD95 (Jo2), B220 (RA3-6B2), (BD Biosciences); CD44
(IM7), CD19 (6D5), CD93 (AA4.1) (BioLegend); Thy1.1 (HIS51, eBioscience). For antiCD19 CAR detection161 Biotin-Protein L (Genscript) was utilized.
For phosphoflow, cells were fixed and permeabilized using the BD Phosflow reagents
and following the manufacturer’s protocol. After permeabilization cells were stained with
pAkt (S473) (D9E) and pS6 (S235/236) (D57.2.2E) from Cell Signaling. For intracellular
cytokine staining, cells were stained with fixable live/dead dye in PBS, then stained for
surface antibodies in FACS buffer, then fixed and permeabilized (BD Biosciences) and
stained for IFNg (XMG1.2, BD Biosciences) and IL-2 (JES6-5H4, BioLegend). For FasL
staining of tumor cells, tumor cells were incubated with vehicle (PBS) or murine IFNg
(100 ng mL-1, BioLegend) for 24h, then stained with FasL (Kay-10) and H-2Db (KH95)
(BD Biosciences). All flow cytometric data were acquired using a BD Fortessa flow
cytometer (Becton Dickinson) and analyzed using FlowJo v. 9.9 software (TreeStar).

Sanger sequencing analysis
Thy1.1-enriched empty- or FasI246N-transduced cells were pelleted and genomic DNA
extracted using the AllPrep DNR/RNA Mini Kit (Qiagen). Primers (IDT) were designed
such that the forward primer was located in Fas upstream of the FasI246N point mutation
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and the reverse primer located in the Thy1.1 reporter. After PCR amplification
(Invitrogen) Sanger sequencing was performed by the NCI Sequencing Core Facility.

Adoptive cell transfer, T cell enumeration, and tumor treatment
For analysis of in vivo persistence, female B6 mice aged 6-12 weeks received 6 Gy total
body irradiation. One day later, were injected by tail vein injection with 5x105
congenically marked pmel-1 T cells transduced with a Thy1.1 containing reporter
construct. Mice were sacrificed on indicated days and splenocytes were analyzed for
homeostatic expansion of congenically marked pmel-1 T cells.
For experiments with pmel-1 T cells and B16 melanoma cells, female B6 mice aged 6-12
weeks were injected with 5x105 cells of a previously described B16 melanoma line143
which overexpresses chimeric human/mouse gp100 antigen KVPRNQDWL (aa25-33).
Ten days later, tumor-bearing mice received 6 Gy total body irradiation. Mice were left
untreated as controls or received by tail vein injection indicated doses of congenically
marked pmel-1 T cells transduced with a Thy1.1 containing reporter construct.
For experiments with anti-CD19 CAR-transduced T cells and 38c13 lymphoma cells,
female C3H mice aged 6-12 weeks were sublethally irradiated with 5 Gy total body
irradiation then injected with 5x105 CD19+ 38c13 lymphoma cells. Four days later,
tumor-bearing mice were left untreated as controls or received by tail vein injection
indicated doses of anti-CD19 CAR-transduced CD8+ T cells also transduced with a
Thy1.1 containing reporter construct.
For experiments with anti-CD19 CAR-transduced T cells and E2a-PBX leukemia cells,
female B6 mice aged 6-12 weeks were injected with 1x106 CD19+ E2a-PBX leukemia
cells. Three days later, tumor-bearing mice received 5 Gy total body irradiation. Mice
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were left untreated as controls or received by tail vein injection indicated doses of antiCD19 CAR-transduced CD8+ T cells also transduced with a Thy1.1 containing reporter
construct. To analyze anti-CD19 CAR-transduced T cell persistence and leukemia
burden, mice were sacrificed after 14d and cellular analysis performed on the spleen and
bone marrow.
For experiments with MRL-Mp mice, female mice aged 8 weeks received 6 Gy total
body irradiation. One day later, these mice were injected with 3x106 of anti-CD19 CARtransduced CD8+ T cells also transduced with a Thy1.1 containing reporter construct.
Age-matched MRL-lpr female mice were left untouched.
All transduced T cells were bead-enriched to >92% purity using anti-Thy1.1 magnetic
microbeads prior to infusion (Miltenyi Biotec). All treated mice received once daily
injections of 12 µg of IL-2 i.p. for 3d except where indicated, when mice received twice
daily injections of IL-2 for 3d. All tumor measurements were performed in a blinded
fashion by an independent investigator.

T cell and tumor cell co-culture assay
After approximately 5-6d in culture, pmel-1 or anti-CD19 CAR-transduced T cells were
washed twice in PBS and plated in IL-2-free T cell media at 5 x 104 cells per well in a 96well round bottom plate. T cells were incubated either alone, with plate-bound antiCD3/CD28 (2 µg/mL, each), with 1.5 x 105 B16-mhgp100 or E2a-PBX cells per well for
an E:T of 1:3, or with 50-100 ng/mL of lz-FasL. Cells were cultured together for 6 or 24h
before being washed and stained for cell viability.
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ELISA assay
Analysis of serum anti-nuclear and anti-dsDNA antibodies was performed on serum
diluted 1:5; ELISA performed according to manufacturer’s instructions (Alpha
Diagnostic International).

Histopathology: Lung tissues were fixed in buffered 10% formalin and stained with
haematoxylin and eosin (H&E). Tissue sections were scored in a blinded manner by an
interpreting pathologist. Scoring: 0 = no specific findings, 1 = mild infiltrates, 2 =
minimal infiltrates, 3 = moderate infiltrates, 4 = severe infiltrates.

Statistical Analysis
The products of perpendicular tumor diameters were plotted as the mean ± SEM for each
data point, and tumor treatment graphs were compared by using the Wilcoxon rank sum
test and analysis of animal survival assessed using a Log-rank Mantel Cox test. For all
other experiments, data were compared using either an unpaired 2-tailed Student’s t test
corrected for multiple comparisons by a Bonferroni adjustment or repeated measures
using a 1- or 2-way ANOVA, as indicated. In all cases, P values of less than 0.05 were
considered significant. Statistics were calculated using Prism 7 GraphPad software
(GraphPad Software Inc.).

Data and Materials Availability
All data reported in the paper are recorded in the manuscript, are available in the
supplemental materials, or though the publicly available databases TCGA
(https://cancergenome.nih.gov/) and UCSC Xena (http://xena.ucsc.edu).
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APPENDIX
Tables
GTEx Tissue Type
Adrenal Gland
Bladder
Whole Blood
Brain - Amygdala
Brain - Anterior Cingulate Cortex (Ba24)
Brain - Caudate (Basal Ganglia)
Brain - Cerebellar Hemisphere
Brain - Cerebellum
Brain - Cortex
Brain - Frontal Cortex (Ba9)
Brain - Hippocampus
Brain - Hypothalamus
Brain - Nucleus Accumbens (Basal Ganglia)
Brain - Putamen (Basal Ganglia)
Brain - Spinal Cord (Cervical C-1)
Brain - Substantia Nigra
Brain - Amygdala
Brain - Anterior Cingulate Cortex (Ba24)
Brain - Caudate (Basal Ganglia)
Brain - Cerebellar Hemisphere
Brain - Cerebellum
Brain - Cortex
Brain - Frontal Cortex (Ba9)
Brain - Hippocampus
Brain - Hypothalamus
Brain - Nucleus Accumbens (Basal Ganglia)
Brain - Putamen (Basal Ganglia)
Brain - Spinal Cord (Cervical C-1)
Brain - Substantia Nigra
Breast - Mammary Tissue
Cervix - Ectocervix
Cervix - Endocervix
Kidney - Cortex
Kidney - Cortex
Colon - Sigmoid
Colon - Transverse
Colon - Sigmoid
Esophagus - Gastroesophageal Junction
Esophagus - Mucosa
Liver
Lung
Lung
Spleen
Adipose - Subcutaneous
Artery - Tibial
Nerve - Tibial
Muscle - Skeletal
Fallopian Tube
Ovary
Prostate

TCGA Cancer Subtype
Adrenocortical Cancer
Bladder Urothelial Carcinoma
Acute Lymphoblastic Leukemia

TCGA Abbr
ACC
BLCA
ALL

Brain Lower Grade Glioma

LGG

Glioblastoma Multiforme

GBM

Breast Invasive Carcinoma

BRCA

Cervical & Endocervical Cancer

CESC

Kidney Clear Cell Carcinoma
Kidney Renal Papillary Cell Carcinoma

KIRC
KIRP

Colon Adenocarcinoma

COAD

Rectum Adenocarcinoma

READ

Esophageal Carcinoma

ESCA

Liver Hepatocellular Carcinoma
Lung Adenocarcinoma
Lung Squamous Cell Carcinoma
Diffuse Large B-Cell Lymphoma

LIHC
LUAD
LUSC
DLBC

Sarcoma

SARC

Ovarian Serous Cystadenocarcinoma
Prostate Adenocarcinoma

OV
PRAD
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Pancreas
Skin - Not Sun Exposed (Suprapubic)
Skin - Sun Exposed (Lower Leg)
Stomach
Testis
Thyroid
Uterus
Uterus
Supplemental Table 1

Pancreatic Adenocarcinoma

PAAD

Skin Cutaneous Melanoma
Stomach Adenocarcinoma
Testicular Germ Cell Tumor
Thyroid Carcinoma
Uterine Carcinosarcoma
Uterine Corpus Endometrioid Carcinoma

SKCM
STAD
TGCT
THCA
UCS
UCEC

Summary of TCGA cancer subtypes and matched tissues of origin from the GTEx database. A list of the normal tissues
of origin and corresponding cancer subtypes were obtained from the Genotype-Tissue Expression (GTEx) and The
Cancer Genome Atlas (TCGA, n=26) datasets, respectively.
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Gene

r

SLA2
0.8580
CD8A
0.8539
CCR5
0.8510
CD2
0.8440
NKG7
0.8394
GZMA
0.8383
KLRK1
0.8337
CRTAM
0.8205
CXCR6
0.8097
SIRPG
0.8039
IFNG
0.8036
UBASH3A
0.8005
EOMES
0.8000
PRF1
0.7911
CD247
0.7882
PYHIN1
0.7822
CD3E
0.7818
CD3D
0.7780
LAG3
0.7708
GZMH
0.7693
CCL4
0.7582
CXCR3
0.7568
GPR174
0.7559
GZMK
0.7358
TIGIT
0.7333
ITGAL
0.7237
IL12RB1
0.7188
LCP2
0.7133
PDCD1
0.7126
SAMD3
0.7113
FAM26F
0.7050
SNX20
0.6990
CTSW
0.6979
FCRL6
0.6945
PSTPIP1
0.6945
HCST
0.6833
SLAMF6
0.6826
SPN
0.6803
CXCL9
0.6795
KLRC4-KLRK1 0.6773
Supplemental Table 2.

Gene

r

Gene

r

Gene

r

Gene

r

CCL5
ARHGAP9
KLRD1
SLFN12L
ARHGAP30
ZNF683
IL10RA
IL18BP
TRAT1
ABCD2
GPR65
SASH3
CD6
SLAMF7
CYTH4
FAM78A
PTPRC
XCL2
RASAL3
CD74
IRF1
SEPT1
ITK
CD53
BIN2
GRAP2
AC008964.1
MYO1F
IL21R
BTN3A3
ICOS
PVRIG
SLAMF8
C1QB
HLA-DPA1
HLA-DRA
TBX21
BTN3A1
FCGR1A
KLRC4

0.6757
0.6747
0.6742
0.6739
0.6597
0.6593
0.6583
0.6576
0.6512
0.6506
0.6502
0.6493
0.6478
0.6440
0.6436
0.6416
0.6414
0.6397
0.6395
0.6386
0.6385
0.6366
0.6359
0.6358
0.6340
0.6332
0.6305
0.6296
0.6285
0.6265
0.6242
0.6240
0.6235
0.6235
0.6229
0.6224
0.6219
0.6217
0.6216
0.6200

NCKAP1L
LILRB1
SIT1
GNGT2
C1QA
TNFAIP8L2
APOL3
FCGR1B
TLR8
DOCK2
IKZF1
LTA
ARHGAP25
HLA-DPB1
TTC24
C1QC
GIMAP2
BTN3A2
WIPF1
TIFAB
GIMAP4
TNFRSF9
APOBEC3H
FCGR3A
IL18RAP
CCR2
CD48
CD72
LAP3
APOBEC3D
SELPLG
DOK2
AD000671.6
AIF1
SLA
APOBEC3G
GBP4
ACAP1
SP140
EVI2B

0.6194
0.6157
0.6144
0.6142
0.6137
0.6107
0.6092
0.6073
0.6069
0.6052
0.6031
0.6025
0.6021
0.6015
0.6014
0.5971
0.5962
0.5936
0.5896
0.5893
0.5892
0.5889
0.5887
0.5885
0.5873
0.5869
0.5851
0.5851
0.5846
0.5836
0.5808
0.5803
0.5802
0.5797
0.5780
0.5778
0.5776
0.5762
0.5752
0.5744

ZAP70
NCR1
MS4A6A
LCK
ARHGAP15
CD86
LAIR1
GBP1
CD200R1
CD4
GBP2
ABI3
HLA-E
PLEK
LAPTM5
SAMHD1
ZNF80
CORO1A
IL16
CLEC2D
C5orf56
GBP5
LILRB2
CARD16
HLA-DQA1
P2RY13
HLA-DOA
FMNL1
SCIMP
C1orf162
IGSF6
PSMB9
EVI2A
HLA-DRB1
FYB
PARVG
P2RY10
LILRB4
WAS
C15orf53

0.5731
0.5723
0.5721
0.5720
0.5680
0.5667
0.5656
0.5605
0.5605
0.5594
0.5590
0.5580
0.5577
0.5570
0.5557
0.5553
0.5547
0.5542
0.5531
0.5506
0.5503
0.5494
0.5467
0.5464
0.5463
0.5462
0.5458
0.5452
0.5446
0.5446
0.5438
0.5435
0.5434
0.5421
0.5420
0.5419
0.5414
0.5412
0.5410
0.5408

PTPRCAP
CD96
STAT1
FCER1G
CST7
IGFLR1
TRAF3IP3
HLA-DMA
CYBB
LAT
TNFRSF1B
ITGB2
CD3G
TBC1D10C
TRIM22
JAK3
CIITA
B2M
GAB3
SIGLEC10
VAV1
TAP1
CXorf21
CD160
NCF1
GIMAP5
PTPN7
FERMT3
LST1
ITGAE
IL2RB
SAMSN1
BTN2A2
GMFG
GIMAP7
APOL6
NLRC5
LY9
GPR31
AKNA

0.5407
0.5387
0.5375
0.5374
0.5370
0.5366
0.5364
0.5362
0.5360
0.5342
0.5342
0.5334
0.5329
0.5304
0.5290
0.5289
0.5288
0.5280
0.5265
0.5264
0.5263
0.5254
0.5239
0.5232
0.5203
0.5200
0.5199
0.5190
0.5189
0.5188
0.5180
0.5160
0.5152
0.5139
0.5119
0.5112
0.5099
0.5092
0.5087
0.5087

A pan-cancer analysis of the top 200 genes positively correlated with FASLG across the TCGA dataset. Gene names
and Pearson’s correlation coefficient (r) to FASLG are listed.
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